RESEARCH ARTICLE

WILEY

Comparison of comorbidities among severe and non-severe COVID-19 patients in Asian versus non-Asian populations: A systematic review and meta-analysis

Anju Puri¹ | Lin He² | Mohan Giri³ | Chengfei Wu¹ | Qinghua Zhao¹

¹Department of Nursing, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

²Department of Respiratory and Critical Care Medicine, Fuling Central Hospital of Chongqing City, Chongqing, China

³Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Correspondence

Qinghua Zhao, Director of department of Nursing, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Lu, Yuzhong District, 400016, Chongqing, People's Republic of China. Email: qh20063@163.com

Funding information

This study was funded by Educational reform for graduate students of Chongqing Municipal Education Commission (approval number: yjg211006) and Science and Technology Innovation Project of "Chengyu Region Double-City Economic Circle Construction" of Chongqing Municipal Education Commission (approval number: KJCX2020018)

Abstract

Objectives: This study aimed to evaluate the comorbidities among severe and non-severe COVID-19 patients in Asian versus non-Asian populations.

Design: Systemic review and Meta-analysis.

Methods: A systematic literature search was conducted using PubMed, Embase, Scopus and the web of science Database up to 24 March 2021. Odds ratios were calculated using a random-effects model.

Results: We identified 66 studies including 39 Asian and 27 non-Asian studies. This study demonstrated that the proportion of hypertension was significantly higher in severe group than in non-severe group for Asian (OR = 2.46) and non-Asian (OR = 1.60, 95% CI: 1.37–1.86, $l^2 = 84\%$; p < .00001) patients. Similarly, the proportion of diabetes, cardiovascular disease and chronic kidney disease was significantly higher in severe group than in non-severe group for both Asian and non-Asian studies. We found no statistically significant difference between the severe versus non-severe group for cancer (OR = 1.26) and chronic obstructive pulmonary disease (OR = 1.32) among non-Asian patients.

KEYWORDS

comorbidity, COVID-19, meta-analysis, SARS-CoV-2, severe

1 | INTRODUCTION

The outbreak of Coronavirus disease (COVID-19), which was first reported in early December 2019 in Wuhan, China has emerged as one of the most serious global pandemic and global health hazard (Huang, Wang, et al., 2020). The cases of COVID-19 are still rapidly increasing with higher morbidity and mortality. Globally, there have been 146,067,511 confirmed COVID-19 patients by 25 April 2021 and among them 3,092,497 lost their lives (World Health Organization, 2021). The clinical manifestations highly range from asymptomatic to symptomatic and shows clusters of flu like symptoms such as fever, fatigue, myalgia, dry cough, dyspnoea, anorexia and so on (Hong et al., 2020; Huang, Wang, et al., 2020; Huang, Lian, et al., 2020). Patients are classified into four type, that is, mild, moderate, severe and critical based on clinical manifestation and laboratory findings. Some studies have documented that

Anju Puri and Lin He are contributed equally to this article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. *Nursing Open* published by John Wiley & Sons Ltd.

734 WILFY_NursingOpen

COVID-19-infected patients who already have pre-existing comorbidities such as hypertension, diabetes, congestive heart failure, cardiovascular diseases, cerebrovascular disease, chronic kidney disease (CKD), chronic liver disease, cancer, chronic obstructive pulmonary disease and asthma leads to poor prognosis or even fatal outcomes (Giri et al., 2020; Gregoriano et al., 2020; Yang, Zheng, et al., 2020; Zhou, Yang, et al., 2020). In addition, the older people who already have above listed underlying chronic conditions are more susceptible to COVID-19. Severe cases admitted in intensive care unit with pre-existing comorbidities yield poorer clinical outcomes than those without (Abohamr et al., 2020; Guan et al., 2020; Huang, Wang, et al., 2020; Tabata et al., 2020).

Thus, it is critical to thoroughly understand and identify the actual high-risk comorbidities, which are closely associated with COVID-19 in order to do prompt management and prevent the deterioration from mild and moderate conditions to the severe ones. Thus far, most of published meta-analysis about the comorbidity in severe COVID-19 patients included limited studies and most studies included in these meta-analysis were conducted in China. Therefore, it is necessary to carry out a meta-analysis to give systematic evaluation of common comorbidities in severe and non-severe COVID-19 patients around the globe. To the best of our knowledge, this is the first study to compare comorbidities among severe and non-severe COVID-19 patients in Asian versus non-Asian populations.

2 | METHODS

2.1 | Eligibility criteria

For research article selection the inclusion criteria were as follows: (1) Study population: Studies with patients diagnosed with COVID-19; (2) Comparative studies: Studies that compared severe or ICU (elevated troponin T (TnT) level as the second choice if severe or ICU data were not given) and non-sever or non-ICU (normal TnT level as the second choice if non-severe or non-ICU data was not given) cases of COVID-19; and (3) The studies reporting parameters of comorbidities such as hypertension, diabetes, cardiovascular disease, cancer, chronic obstructive pulmonary disease and chronic kidney disease. Non-English studies, letters, case studies, editorials, conference abstract, vaccination trials studies and articles with only abstract were excluded. Studies with fewer than 20 cases were also excluded.

2.2 | Information sources and Searching strategies

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines (Moher et al., 2009). PRISMA checklist was followed step by step (Electronic Supplementary information Appendix S1). We used PubMed, Embase, Scopus and Web of Science online database to conduct a comprehensive search up to 24 March 2021, with following search terms: "COVID-19," "Novel coronavirus," "SARS-CoV-2," "Coronavirus disease-19," "Epidemiological character," "Clinical features," "Clinical character," "Clinical Presentation," "comorbidities," "Comorbidities" and "Complications." Full electronic search strategy in PubMed database can be found here (Electronic Supplementary information Appendix S2). We applied search filters to include English language studies. We screened reference lists of included studies to ensure literature saturation.

2.3 | Data extraction

Microsoft Excel database was used to record all available information. Two authors (AP and LH) who performed the literature search also independently extracted following items from each article: first author, publication year, country, study design, age, gender, sample size and number of people in severe and non-severe group. In case of missing data, we also contacted the authors of an article to obtain more precise data about the comorbidities of the patients evaluated. Disagreement occurred during research period were resolved by consensus with third author. The primary outcome measure was to compare the proportion of comorbidities such as hypertension, diabetes, cardiovascular disease, and chronic kidney disease in severe group versus non-severe group for both Asian and non-Asian studies.

2.4 | Risk of bias assessment

Methodological index for non-randomized studies (MINORS) (Slim et al., 2003) was used to assess methodological quality of included studies by two independent researchers. Each item in the MINORS has three scores: 0, unreported; 1, reported but inadequately or partially; and 2, adequately reported. The total score is 24. The detailed risk of bias for all the included studies using MINORS criteria score is presented in Table 1. According to MINORS criteria score the studies were classified as very low quality (0–6), low quality (7–12), moderate quality (13–18) and high quality (19–24). Two reviewers independently assessed the quality of included studies and disagreements were resolved through discussion with third reviewer. Publication bias among included studies was assessed by funnel plots and a symmetrical plot indicated low-risk publication bias.

2.5 | Statistical analysis

Meta-analysis was performed using RevMan software version 5.3. We calculated pooled odds ratio (OR) and 95% CI for comorbidities, in severe versus non-severe Asian and non-Asian studies. Heterogeneity between studies was assessed using the Cochran Q test and l^2 statistics. Generally, in cases of l^2 being larger than 50%, a random-effect model is used, otherwise a fixed-effect model is used. However, owing to the clinical heterogeneity inherent in

 TABLE 1
 MINORS rating scale for quality of included studies

-WILEY

Study	1	2	3	4	(5)	6	$\overline{\mathcal{O}}$	(8)	9	(10)	(1)	(12)	Score
Asian studies													
Abohamr SI	2	2	2	2	2	0	1	0	2	2	2	2	19
Alqahtani AM	2	2	2	2	2	1	0	0	2	2	2	2	19
Bastug A	2	2	2	2	2	0	2	0	2	2	2	2	20
Cao J	2	2	2	2	2	1	0	0	2	2	2	2	19
Cao Z	2	2	2	2	2	0	1	0	2	2	2	2	19
Du RH	2	2	2	2	2	0	2	0	2	2	2	2	20
Guan WJ	2	2	2	2	2	0	0	0	2	2	2	2	18
Güner R	2	2	2	2	2	0	1	0	2	2	2	2	19
Guo T	2	2	2	2	2	0	0	0	2	2	2	2	18
Hong KS	2	2	2	2	2	0	1	0	2	2	2	2	19
Huang C	2	2	2	2	2	1	2	0	2	2	2	2	21
Huang R	2	2	2	2	2	1	1	0	2	2	2	2	20
Khamis F	2	2	2	2	2	0	2	0	2	2	2	2	20
Khan A	2	2	2	2	2	1	1	0	2	2	2	2	20
Lee JY	2	2	2	2	2	0	1	0	2	2	2	2	19
Lee SG	2	2	2	2	2	0	0	0	2	2	2	2	18
Li C	2	2	2	2	2	1	1	0	2	2	2	2	20
LI K	2	2	2	2	2	1	0	0	2	2	2	2	19
Li X	2	2	2	2	2	0	1	0	2	2	2	2	19
Lv Z	2	2	2	2	2	0	2	0	2	2	2	2	20
Omrani A	2	2	2	2	2	1	1	0	2	2	2	2	20
Shabrawishi M	2	2	2	2	2	0	1	0	2	2	2	2	19
Shahriarirad R	2	2	2	2	2	0	1	0	2	2	2	2	19
Shi S	2	2	2	2	2	1	2	0	2	2	2	2	21
Tabata S	2	2	2	2	2	0	0	0	2	2	2	2	18
Tian S	2	2	2	2	2	1	1	0	2	2	2	2	20
Wan S	2	2	2	2	2	1	1	0	2	2	2	2	20
Wang D	2	2	2	2	2	1	2	0	2	2	2	2	21
Wang W	2	2	2	2	2	0	2	0	2	2	2	2	20
Wang Y	2	2	2	2	2	1	0	0	2	2	2	2	19
Wang Z	2	2	2	2	2	1	2	0	2	2	2	2	21
Wei Y	2	2	2	2	2	1	1	0	2	2	2	2	20
Wu J	2	2	2	2	2	1	1	0	2	2	2	2	20
Xiong F	2	2	2	2	2	0	0	0	2	2	2	2	18
Xiong S	2	2	2	2	2	1	1	0	2	2	2	2	20
Yang L	2	2	2	2	2	0	0	0	2	2	2	2	18
Zhang G	2	2	2	2	2	0	1	0	2	2	2	2	19
Zhang JJ	2	2	2	2	2	0	0	0	2	2	2	2	18
Zhou J	2	2	2	2	2	0	0	0	2	2	2	2	18
Non-Asian studies													
Argenziano MG	2	2	2	2	2	1	2	0	2	2	2	2	21
Buckner FS	2	2	2	2	2	0	1	0	2	2	2	2	19
Cattelan AM	2	2	2	2	2	0	0	0	2	2	2	2	18
Ferguson J	2	2	2	2	2	1	1	0	2	2	2	2	20

TABLE 1 (Continued)

Study	1	2	3	4	(5)	6	$\overline{\boldsymbol{\mathcal{I}}}$	(8)	9	10	(1)	(12)	Score
Filardo TD	2	2	2	2	2	0	1	0	2	2	2	2	19
Garibaldi BT	2	2	2	2	2	0	0	0	2	2	2	2	18
Giustino G	2	2	2	2	2	1	1	0	2	2	2	2	20
Gregoriano C	2	2	2	2	2	1	0	0	2	2	2	2	19
Israelsen SB	2	2	2	2	2	0	0	0	2	2	2	2	18
Jourdes A	2	2	2	2	2	1	1	0	2	2	2	2	20
Kaeuffer C	2	2	2	2	2	0	0	0	2	2	2	2	18
Lombardi CM	2	2	2	2	2	0	1	0	2	2	2	2	19
Matangila JR	2	2	2	2	2	0	2	0	2	2	2	2	20
Ortiz-Brizuela E	2	2	2	2	2	0	0	0	2	2	2	2	18
Oud L	2	2	2	2	2	0	1	0	2	2	2	2	19
Pellaud C	2	2	2	2	2	1	1	0	2	2	2	2	20
Petrilli CM	2	2	2	2	2	0	0	0	2	2	2	2	18
Popov GT	2	2	2	2	2	0	0	0	2	2	2	2	18
Raad M	2	2	2	2	2	0	1	0	2	2	2	2	19
Reilev M	2	2	2	2	2	0	1	0	2	2	2	2	19
Samuels S	2	2	2	2	2	0	2	0	2	2	2	2	20
Schönfeld D	2	2	2	2	2	1	0	0	2	2	2	2	19
Stefan, G.	2	2	2	2	2	0	1	0	2	2	2	2	19
Sulejmani A	2	2	2	2	2	0	0	0	2	2	2	2	18
Suleyman G	2	2	2	2	2	0	1	0	2	2	2	2	19
Turcotte JJ	2	2	2	2	2	0	1	0	2	2	2	2	19
Yazdanpanah Y	2	2	2	2	2	1	1	0	2	2	2	2	20

Note: ① A clearly stated aim; ② Inclusion of consecutive patients; ③ Prospective collection of data; ④ Endpoints appropriate to the aim of the study; ⑤ Unbiased assessment of the study endpoint; ⑥ Follow-up period appropriate to the aim of the study; ⑦ Loss to follow up less than 5%;
⑧ Prospective calculation of the study size. ④ Appropriate selection of control group; ⑩ Synchronization of control group; ⑪ Baseline comparable between groups; ⑫ Appropriately statistical analysis. The global ideal score being 24 for comparative studies.

the data and the different effect sizes of included studies we used random-effects analysis for all meta-analyses. The l^2 values of <25%, 25%–50%, 50%–75% and 75%–100% were regarded as homogeneous, low, moderate and high heterogeneous levels, respectively. The *p*-value less than 0.05 was used to indicate statistical significance.

3 | RESULTS

Searches in electronic databases found 11,874 articles. After excluding duplicates (N = 7318), 4,556 citation records remained. Thereafter, 4,556 articles were screened in terms of title and abstract. 4,442 ineligible studies were excluded. The full text of 114 studies was assessed to determine their eligibility. We excluded 48 full texts, comprising 24 review articles, 15 non-comparative studies, five meta-analysis and four editorials. Ultimately, out of 114 full text article finally 66 articles, which met the inclusion criteria were included in the final analysis. Figure 1 shows a flow chart of studies selection process.

3.1 | Study characteristics and quality

A total of 66 studies were included among them 39 studies were Asian and 27 were non-Asian. Out of 39 Asian studies, most of them were carried out in China (N = 26) (Cao, Li, et al., 2020; Cao, Zheng, et al., 2020; Du et al., 2020; Guan et al., 2020; Guo et al., 2020; Huang, Wang, et al., 2020; Huang, Zhu, et al., 2020; Li, Jiang, et al., 2020; Li, Wu, et al., 2020; Li, Xu, et al., 2020; Lv et al., 2020; Shi et al., 2020; Tian et al., 2020; Wan et al., 2020; Wang, Hu, et al., 2020; Wang, Xin, et al., 2020; Wang, Yang, et al., 2020; Wang, Zhen, et al., 2020; Wei et al., 2020; Wu et al., 2020; Xiong, Liu, et al., 2020; Xiong, Tang, et al., 2020; Yang, Liu, et al., 2020; Zhang, Dong, et al., 2020; Zhang, Hu, et al., 2020; Zhou, Sun, et al., 2020), followed by Saudi Arabia (N = 4) (Abohamr et al., 2020; Algahtani et al., 2020; Khan et al., 2020; Shabrawishi et al., 2020), South Korea (N = 3) (Hong et al., 2020; Lee, Hong, et al., 2020; Lee, Park, et al., 2020), Turkey (N = 2) (Bastug et al., 2020; Güner et al., 2020), Oman (N = 1) (Khamis et al., 2020), Qatar (N = 1) (Omrani et al., 2020), Iran (N = 1) (Shahriarirad et al., 2020), and Japan (N = 1) (Tab ata et al., 2020). Most of the non-Asian studies

737



FIGURE 1 Flow diagram of study selection process

were conducted in United States (N = 12) (Argenziano et al., 2020; Buckner et al., 2020; Ferguson et al., 2020; Filardo et al., 2020; Garibaldi et al., 2021; Giustino et al., 2020; Oud & Garza, 2021; Petrilli et al., 2020; Raad et al., 2020; Samuels et al., 2021; Suleyman et al., 2020; Turcotte et al., 2020), followed by Italy (N = 3) (Cattelan et al., 2020; Lombardi et al., 2020; Sulejmani et al., 2021), France (N = 3) (Jourdes et al., 2020; Kaeuffer et al., 2020; Yazdanpanah, 2021), Switzerland (N = 2) (Gregoriano et al., 2020; Pellaud et al., 2020), Denmark (N = 2)(Israelsen et al., 2020; Reilev et al., 2020), Congo (N = 1) (Matangila et al., 2020), Mexico (N = 1) (Ortiz-Brizuela et al., 2020), Bulgaria (N = 1) (Popov et al., 2020), Argentina (N = 1) (Schönfeld et al., 2021) and Romania (N = 1) (Stefan et al., 2021). All included studies were published in 2020 and 2021 with varying sample size that ranged from 37 to 207,079 patients. The characteristics of the included studies are depicted in Table 2. We performed assessments of risk of bias for all the included studies using MINORS rating scale and reported in Table 1. The mean MINORS score was 19.23 ± 0.91 (range: 18–21) out of a possible 24 for comparative studies (Table 1). All of the included studies were moderate-to-high quality.

3.2 | Hypertension in Asian and non-Asian population

Fifty eight studies reported data on hypertension in severe and non-severe COVID-19 patients. The overall pooled incidence of

TABLE 2 Characteristics of the included studies

		Sev		Severe patients		Non-sever patients		
Study	Type of study design	Country	Total patients	Age, years ^a	Male	Age, years ^a	Male	
Asian studies								
Abohamr SI	Retrospective	Saudi Arabia	768	47.4 ± 13.8	284	45.5 ± 13.5	305	
Alqahtani AM	Retrospective	Saudi Arabia	458	NA	37	NA	361	
Bastug A	Retrospective	Turkey	191	71 (28-91)	26	43 (18-83)	81	
Cao J	Retrospective	China	244	62.20 ± 13.43	63	59.79 ± 13.49	44	
Cao Z	Retrospective	China	80	71 ± 15	16	44 ± 16	22	
Du RH	Retrospective	China	109	68.4 ± 9.7	36	72.7 ± 11.6	38	
Guan WJ	Retrospective	China	1099	52 (40-65)	100	45 (34–57)	537	
Güner R	Cohort	Turkey	222	62.2 ± 11.9	33	47.7 ± 16.1	99	
Guo T	Retrospective	China	187	71.4 ± 9.43	34	53.53 ± 13.22	57	
Hong KS	Retrospective	South Korea	98	63.2 ± 10.1	6	54.2 ± 17.7	32	
Huang C	Prospective	China	41	49 (41–61)	11	49 (41–57.5)	19	
Huang R	Retrospective	China	202	49 (35–59)	17	44 (33–53)	99	
Khamis F	Retrospective	Oman	63	50 ± 17	21	47 ± 16	32	
Khan A	Retrospective	Saudi Arabia	648	37 (27)	52	33 (18)	290	
Lee JY	Retrospective	South Korea	694	NA	57	NA	155	
Lee SG	Retrospective	South Korea	7339	66.8 ± 15.2	441	44.2 ± 17.8	2529	
Li C	Retrospective	China	2068	69 (60–78)	282	61 (49–68)	723	
LI K	Retrospective	China	83	53.7 ± 12.3	15	41.9 ± 10.6	29	
Li X	Retrospective	China	548	65 (54–72)	153	56 (44-66)	126	
Lv Z	Retrospective	China	354	62 (25-89)	77	61 (23–79)	58	
Omrani AS	Retrospective	Qatar	5000	49.5 (39.5–60)	100	38 (30-49)	1067	
Shabrawishi M	Retrospective	Saudi Arabia	150	49.8 ± 15.7	13	45.4 ± 16	58	
Shahriarirad R	Retrospective	Iran	113	NA	7	NA	64	
Shi S	Cohort	China	416	74 (34–95)	44	60 (21–90)	161	
Tabata S	Retrospective	Japan	104	73 (55–77)	17	60 (40-71)	22	
Tian S	Retrospective	China	262	61.4 (1-94)	26	44.5 (1–93)	101	
Wan S	Retrospective	China	135	56 (52–73)	21	44 (33-49)	52	
Wang D	Retrospective	China	138	66 (57–78)	22	51 (37–62)	53	
Wang W	Retrospective	China	421	56 (45-63)	28	51 (38–60)	186	
Wang Y	Retrospective	China	222	70 (65.5–80)	12	60.5 (48–67)	96	
Wang Z	Retrospective	China	69	70.5 (62–77)	7	37 (32–51)	25	
Wei Y	Retrospective	China	276	65 (60-72.8)	10	50 (39–57)	145	
Wu J	Retrospective	China	280	63.04 ± 10.20	45	37.55 ± 17.10	106	
Xiong F	Retrospective	China	131	63.3 ± 12.4	17	63.1 ± 13.4	58	
Xiong S	Retrospective	China	116	64 (53–76)	38	56 (37–64)	42	
Yang L	Retrospective	China	200	71 ± 13.4	16	52 ± 16.2	82	
Zhang G	Retrospective	China	221	62 (52–74)	35	51 (36-64.3)	73	
Zhang JJ	Retrospective	China	140	64 (25-87)	33	51.5 (26–78)	38	
Zhou J	Retrospective	China	201	57 (46-66)	27	40 (31–53)	75	
Non-Asian studies								
Argenziano MG	Retrospective	USA	1000	62 (52–72)	158	64 (51–77)	353	
Buckner FS	Retrospective	USA	105	70 (23-97)	30	67 (25-96)	23	
Cattelan AM	Retrospective	Italy	303	68 (56-77)	53	60 (47–72)	129	

(Continues)

TABLE 2 (Continued)

Study Type of study design Country Total patients Age, years ^a Male Age, years ^a Male Ferguson J Retrospective USA 72 NA NA NA NA NA Filardo TD Retrospective USA 270 $60(51-68)$ 95 $57(48-67)$ 87 Garibaldi BT Cohort USA 832 $58(51-70)$ 96 $60(45-72)$ 266 Giustino G Retrospective USA 305 $66(56-74)$ 132 $58(47-70)$ 73 Gregoriano C Retrospective Switzerland 99 $69(57-75)$ 28 $63.5(56-76)$ 34 Jourdes A Cohort France 263 $67(56-73)$ 33 $64(53-76)$ 122 Kaeuffer C Prospective France 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CM Retrospective Congo 160 $58(50-70)$ 31 $51(35-61)$ 41 <	
Ferguson J Retrospective USA 72 NA NA NA NA Filardo TD Retrospective USA 270 60 (51-68) 95 57 (48-67) 87 Garibaldi BT Cohort USA 832 58 (51-70) 96 60 (45-72) 266 Giustino G Retrospective USA 305 66 (56-74) 132 58 (47-70) 73 73 Gregoriano C Retrospective Switzerland 99 69 (57-75) 28 63.5 (56-76) 34 Israelsen SB Retrospective Denmark 175 68 (60-72) 16 73 (55-83) 69 Jourdes A Cohort France 263 67 (56-73) 33 64 (53-76) 122 Kaeuffer C Prospective France 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CM Retrospective Mexico 309 53 (40-64) 20 48 (29-60.5) 65 Oud L Cohort USA <th></th>	
Filardo TD Retrospective USA 270 60 (51-68) 95 57 (48-67) 87 Garibaldi BT Cohort USA 832 58 (51-70) 96 60 (45-72) 266 Giustino G Retrospective USA 305 66 (56-74) 132 58 (47-70) 73 Gregoriano C Retrospective Switzerland 99 69 (57-75) 28 63.5 (56-76) 34 Israelsen SB Retrospective Denmark 175 68 (60-72) 16 73 (55-83) 69 Jourdes A Cohort France 263 67 (56-73) 33 64 (53-76) 122 Kaeuffer C Prospective France 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CM Retrospective Italy 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JR Retrospective Congo 160 58 (50-70) 31 51 (35-61) 41 Ortiz-Brizuela E Prospective	
Garibaldi BTCohortUSA 832 $58 (51-70)$ 96 $60 (45-72)$ 266 Giustino GRetrospectiveUSA 305 $66 (56-74)$ 132 $58 (47-70)$ 73 Gregoriano CRetrospectiveSwitzerland 99 $69 (57-75)$ 28 $63.5 (56-76)$ 34 Israelsen SBRetrospectiveDenmark 175 $68 (60-72)$ 16 $73 (55-83)$ 69 Jourdes ACohortFrance 263 $67 (56-73)$ 33 $64 (53-76)$ 122 Kaeuffer CProspectiveFrance 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58 (50-70)$ 31 $51 (35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53 (40-64)$ 20 $48 (29-60.5)$ 65 Oud LCohortUSA $136,728$ NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65 (56-71)$ 30 $74 (61-83)$ 89 Petrilli CMCohortUSA 2729 $68 (58-78)$ 656 $60 (48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280 <tr<< td=""><td></td></tr<<>	
Giustino GRetrospectiveUSA 305 $66(56-74)$ 132 $58(47-70)$ 73 Gregoriano CRetrospectiveSwitzerland 99 $69(57-75)$ 28 $63.5(56-76)$ 34 Israelsen SBRetrospectiveDenmark 175 $68(60-72)$ 16 $73(55-83)$ 69 Jourdes ACohortFrance 263 $67(56-73)$ 33 $64(53-76)$ 122 Kaeuffer CProspectiveFrance 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58(50-70)$ 31 $51(35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53(40-64)$ 20 $48(29-60.5)$ 65 Oud LCohortUSA $136,728$ NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65(56-71)$ 30 $74(61-83)$ 89 Petrilli CMCohortUSA 2729 $68(58-78)$ 656 $60(48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70(51-89)$ 229 $59(39-79)$ 280 Reilau MCohortDamaerk 111122 $68(68-75)$ 228 $72(55-81)$ 894	
Gregoriano CRetrospectiveSwitzerland9969 (57-75)2863.5 (56-76)34Israelsen SBRetrospectiveDenmark175 $68 (60-72)$ 16 $73 (55-83)$ 69Jourdes ACohortFrance263 $67 (56-73)$ 33 $64 (53-76)$ 122Kaeuffer CProspectiveFrance1045 67.3 ± 13.4 303 65.6 ± 17.4 309Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234Matangila JRRetrospectiveCongo160 $58 (50-70)$ 31 $51 (35-61)$ 41Ortiz-Brizuela EProspectiveMexico309 $53 (40-64)$ 20 $48 (29-60.5)$ 65 Oud LCohortUSA136,728NA $79,184$ NA2665Pellaud CRetrospectiveSwitzerland196 $65 (56-71)$ 30 $74 (61-83)$ 89 Petrilli CMCohortUSA2729 $68 (58-78)$ 656 $60 (48-71)$ 1016 Popov GTRetrospectiveBulgaria138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280 Reilau MCohortUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280	
Israelsen SBRetrospectiveDenmark175 $68 (60-72)$ 16 $73 (55-83)$ 69 Jourdes ACohortFrance 263 $67 (56-73)$ 33 $64 (53-76)$ 122 Kaeuffer CProspectiveFrance 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58 (50-70)$ 31 $51 (35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53 (40-64)$ 20 $48 (29-60.5)$ 65 Oud LCohortUSA 136728 NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65 (56-71)$ 30 $74 (61-83)$ 89 Petrilli CMCohortUSA 2729 $68 (58-78)$ 656 $60 (48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280 Desinct MCohortDesmark 11122 $68 (68 (75))$ 238 $72 (55 (81))$ $98 (4)$	
Jourdes ACohortFrance 263 $67(56-73)$ 33 $64(53-76)$ 122 Kaeuffer CProspectiveFrance 1045 67.3 ± 13.4 303 65.6 ± 17.4 309 Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58(50-70)$ 31 $51(35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53(40-64)$ 20 $48(29-60.5)$ 65 Oud LCohortUSA $136,728$ NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65(56-71)$ 30 $74(61-83)$ 89 Petrilli CMCohortUSA 2729 $68(58-78)$ 656 $60(48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70(51-89)$ 229 $59(39-79)$ 280 Pailor MCohortUSA 1020 $70(51-89)$ 229 $59(39-79)$ 280	
Kaeuffer CProspectiveFrance1045 67.3 ± 13.4 303 65.6 ± 17.4 309Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58 (50-70)$ 31 $51 (35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53 (40-64)$ 20 $48 (29-60.5)$ 65 Oud LCohortUSA $136,728$ NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65 (56-71)$ 30 $74 (61-83)$ 89 Petrilli CMCohortUSA 2729 $68 (58-78)$ 656 $60 (48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280 Pailor MCabartDonmark 11122 $68 (58,75)$ 238 $73 (55, 91)$ 984	
Lombardi CMRetrospectiveItaly 614 71.3 ± 12 201 64 ± 13.6 234 Matangila JRRetrospectiveCongo 160 $58 (50-70)$ 31 $51 (35-61)$ 41 Ortiz-Brizuela EProspectiveMexico 309 $53 (40-64)$ 20 $48 (29-60.5)$ 65 Oud LCohortUSA $136,728$ NA $79,184$ NA 2665 Pellaud CRetrospectiveSwitzerland 196 $65 (56-71)$ 30 $74 (61-83)$ 89 Petrilli CMCohortUSA 2729 $68 (58-78)$ 656 $60 (48-71)$ 1016 Popov GTRetrospectiveBulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad MRetrospectiveUSA 1020 $70 (51-89)$ 229 $59 (39-79)$ 280 Pailou MCabartDapmark 11122 $68 (58,75)$ 238 $73 (55, 91)$ 894	
Matangila JR Retrospective Congo 160 58 (50-70) 31 51 (35-61) 41 Ortiz-Brizuela E Prospective Mexico 309 53 (40-64) 20 48 (29-60.5) 65 Oud L Cohort USA 136,728 NA 79,184 NA 2665 Pellaud C Retrospective Switzerland 196 65 (56-71) 30 74 (61-83) 89 Petrilli CM Cohort USA 2729 68 (58-78) 656 60 (48-71) 1016 Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailor M Cohort Dopmark 11122 68 (58,75) 238 73 (55, 91) 94	
Ortiz-Brizuela E Prospective Mexico 309 53 (40-64) 20 48 (29-60.5) 65 Oud L Cohort USA 136,728 NA 79,184 NA 2665 Pellaud C Retrospective Switzerland 196 65 (56-71) 30 74 (61-83) 89 Petrilli CM Cohort USA 2729 68 (58-78) 656 60 (48-71) 1016 Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailor M Cohort Dapmark 11122 68 (58,75) 238 73 (55, 91) 984	
Oud L Cohort USA 136,728 NA 79,184 NA 2665 Pellaud C Retrospective Switzerland 196 65 (56-71) 30 74 (61-83) 89 Petrilli CM Cohort USA 2729 68 (58-78) 656 60 (48-71) 1016 Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailor M Cohort Dopmark 11 122 68 (58,75) 238 73 (55, 91) 984	
Pellaud C Retrospective Switzerland 196 65 (56-71) 30 74 (61-83) 89 Petrilli CM Cohort USA 2729 68 (58-78) 656 60 (48-71) 1016 Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailov M Cohort Dopmark 11 122 68 (58, 75) 238 73 (55, 81) 894	
Petrilli CM Cohort USA 2729 68 (58-78) 656 60 (48-71) 1016 Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailov M Cohort Dopmark 11 122 68 (58, 75) 238 73 (55, 91) 984	
Popov GT Retrospective Bulgaria 138 63 ± 12.8 33 48.3 ± 15.7 54 Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Poilov M Cobort Depmark 11 122 68 (58, 75) 238 73 (55, 91) 984	
Raad M Retrospective USA 1020 70 (51-89) 229 59 (39-79) 280 Pailov M Cohort Depmark 11 122 68 (58, 75) 229 72 (55, 91) 984	
Deiloy M. Cohort Denmark 11.122 69.(59.75) 229 72.(55.91) 094	
Reliev M Colloit Deliliark 11,122 06 (36-73) 226 72 (33-61) 764	
Samuels S Retrospective USA 1692 65 ± 16.1 90 62 ± 19.1 166	
Schönfeld D Cohort Argentina 207,079 66 (54–76) 3499 55 (37–72) 22,18	33
Stefan G Cohort Romania 37 67 (60-72) 5 62 (52-67) 14	
Sulejmani A Retrospective Italy 175 74 (60-81) 90 61 (57-72) 15	
Suleyman G Retrospective USA 463 63.8 ± 5.4 80 59.8 ± 15.2 85	
Turcotte JJ Retrospective USA 117 70.2 ± 12.1 26 62.6 ± 16.9 36	
Yazdanpanah Y Cohort France 246 68 (53-76) 51 60 (49-72) 88	

^aAge is presented as median (IQR) or mean \pm SD.

hypertension was significantly higher in severe patients (50.90%) compared to non-severe patients (30.71%). In subgroup analysis, the proportion of hypertension was significantly higher in severe group than in non-severe group for Asian studies (OR = 2.46, 95% CI: 1.94–3.11; p < .00001) (Table 3 and Figure 2). There was high heterogeneity among the included studies ($l^2 = 82\%$). Similarly, non-Asian studies also showed statistically significant difference in hypertension incidence in severe and non-severe patients (OR = 1.60, 95% CI: 1.37–1.86, $l^2 = 84\%$; p < .00001) (Table 3 and Figure 2).

3.3 | Diabetes in Asian and non-Asian population

Data on the diabetes were reported in the 62studies. The overall pooled estimate showed significantly higher incidence of diabetes in severe patients than non-severe patients (OR = 1.95, 95% CI: 1.71–2.22, $l^2 = 83\%$; p < .001) (Table 3 and Figure 3). In Asian studies, the proportion of diabetes was statistically significant higher in severe patients compared with non-severe patients (OR = 2.70, 95% CI: 2.16–3.37, $l^2 = 71\%$; p < .00001). In non-Asian studies, the pooled odds of diabetes was also significantly higher in patients with severe disease than in those without (OR = 1.44, 95% CI: 1.27–1.63, $l^2 = 75\%$; p < .00001) (Table 3 and Figure 3).

3.4 | Cardiovascular disease in Asian and non-Asian population

Pooled findings of 48studies revealed significantly higher incidence of cardiovascular disease in severe patients compared to non-severe patients (OR = 2.47, 95% CI: 2.00–3.06, $l^2 = 79\%$; p < .00001) (Table 3 and Figure 4). The subgroup analysis of both Asian (OR = 3.72, 95% CI: 2.87–4.81, $l^2 = 62\%$; p < .00001) and non-Asian (OR = 1.52, 95% CI: 1.20–1.92, $l^2 = 71\%$; p = .0005) (Table 3 and Figure 4) studies demonstrated statistically significant differences in cardiovascular disease incidence between severe and non-severe patients.

3.5 | Cancer in Asian and non-Asian population

Data on cancer were reported by forty seven studies and pooled analysis revealed significantly higher incidence of cancer in severe

TABLE 3 Analysis of severe and non-severe patients of COVID-19 by using Mantel-Haenszel test

	Number of					0.	01		
Variable	studies	OR	95% CI	Severe	Non-severe	χ^{2a}	1 ²⁶	Z ^c	р
Overall studies									
Hypertension	58	2.01	1.75-2.32	6745	21,542	354.50	84	9.73	<.00001
Diabetes	62	1.95	1.71-2.22	51,816	12,662	367.68	83	9.95	<.00001
Cancer	47	1.63	1.29-2.06	15,467	3829	258.72	82	4.07	<.0001
COPD	39	2.04	1.60-2.61	1009	2996	104.82	64	5.77	<.00001
Cardiovascular disease	48	2.47	2.00-3.06	1477	2182	228.96	79	8.31	<.00001
Chronic kidney disease	38	2.23	1.77-2.81	35,985	3388	273.27	86	6.81	<.00001
Asian studies									
Hypertension	34	2.46	1.94-3.11	1425	2827	181.46	82	7.5	<.00001
Diabetes	36	2.70	2.16-3.37	1011	1802	121.19	71	8.70	<.00001
Cancer	29	2.31	1.68-3.18	162	275	39.27	29	5.17	<.00001
COPD	24	4.04	3.05-5.34	116	136	23.22	1	9.76	<.00001
Cardiovascular disease	29	3.72	2.87-4.81	563	790	73.33	62	9.97	<.00001
Chronic kidney disease	20	3.24	2.01-5.23	168	155	48.92	61	4.81	<.00001
Non-Asian studies									
Hypertension	24	1.60	1.37-1.86	5320	18,715	94.99	76	5.97	<.00001
Diabetes	26	1.44	1.27-1.63	50,805	10,860	98.98	75	5.75	<.00001
Cancer	18	1.26	0.96-1.64	15,305	3554	134.88	87	1.65	.10
COPD	15	1.32	1.02-1.70	893	2860	41.16	66	2.15	.03
Cardiovascular disease	19	1.52	1.20-1.92	914	1392	61.64	71	3.46	.0005
Chronic kidney disease	18	1.97	1.39-2.30	35,817	3233	172.20	90	4.52	<.00001

Abbreviations: 95% CI, 95% confidence interval; COPD, Chronic obstructive pulmonary disease; OR, odds ratio.

^aChi-squared test for heterogeneity.

 ${}^{\rm b}I^2$ index to quantify the degree of heterogeneity.

^cZ-statistics.

patients than non-severe patients (OR = 1.63, 95% CI: 1.29–2.06, $l^2 = 82\%$; p < .0001) (Table 3 and Figure 5). Furthermore, Asian studies showed statistically significant difference in cancer incidence between severe and non-severe patients (OR = 2.31, 95% CI: 1.68–3.18, $l^2 = 29\%$; p < .00001), while no statistically significant differences in cancer incidence were noted for non-Asian patients with COVID-19 (OR = 1.26, 95% CI: 0.96–1.64, $l^2 = 87\%$; p = .10) (Table 3 and Figure 5) in subgroup analysis.

3.6 | Chronic obstructive pulmonary disease (COPD) in Asian and non-Asian population

About the COPD thirty nine studies reported data in severe and nonsevere COVID-19 patients. Pooled summary revealed significantly higher incidence of COPD in severe patients compared to non-severe patients (OR = 2.04, 95% CI: 1.60–2.6, $I^2 = 64\%$; p < .00001) (Table 3 and Figure 6). In subgroup analysis Asian studies showed statistically significant difference in COPD incidence between severe and nonsevere patients (OR = 4.04, 95% CI: 3.05–5.34, $I^2 = 1\%$; p < .00001) (Table 3 and Figure 6). However, no statistically significant differences in COPD incidence were observed between severe versus non-severe for non-Asian patients (OR = 1.32, 95% CI: 1.02–1.70, $I^2 = 66\%$; p = .03).

3.7 | Chronic kidney disease in Asian and non-Asian population

In terms of chronic kidney disease, thirty eight studies reported data in severe and non-severe COVID-19 patients. Compared with nonsevere, severe patients revealed significantly higher incidence of chronic kidney disease in pooled analysis (OR = 2.23, 95% CI: 1.77– 2.8, $l^2 = 86\%$; p < .00001) (Table 3 and Figure 7). Additionally, there was statistically significant differences in both Asian (OR = 3.24, 95% CI: 2.01–5.23, $l^2 = 61\%$; p < .00001) and non-Asian (OR = 1.79, 95% CI: 1.39–2.30, $l^2 = 90\%$; p < .00001) (Table 3 and Figure 7) studies in terms of chronic kidney disease severity in subgroup analysis.

3.8 | Publication bias

Funnel plots for all six comorbidities are included in supplementary information (Figures S1–S6). Nearly symmetrical graphical funnel

	Seve	re	Non-se	vere		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl
2.1.1 Asian studies	1.1.1	350	125	416	2.6%	1 56 [1 15 2 10]	—
Abonamr Si Algahtani AM	36	352	125	410	2.0%	1.00 [1.10, 2.10] 92 81 [39 26 219 36]	→
Bastug A	15	46	12	145	1.4%	5 36 [2 28 12 60]	
Cao J	41	107	21	91	1.8%	2.07 [1.11, 3.87]	
Cao Z	4	27	16	53	0.9%	0.40 [0.12, 1.35]	
Du RH	29	51	36	58	1.6%	0.81 [0.37, 1.73]	
Guan WJ	41	173	124	926	2.3%	2.01 [1.35, 2.99]	
Guner R	16	50	36	172	1.7%	1.78 [0.88, 3.57]	
Guo T	33	52	28	135	1.7%	6.64 [3.29, 13.38]	
Hong KS	5	13	25	85	0.9%	1.50 [0.45, 5.03]	
Huang C	2	13	4	28	0.5%	1.09 [0.17, 6.88]	•
Huang R	2	23	27	179	0.7%	0.54 [0.12, 2.42]	
Khamis F	1	24	13	39	1.0%	0.82 [0.27, 2.48]	
Knan A	10	107	59	5/1	1.9%	2.28 [1.23, 4.20]	
	371	927	1002	6412	2.3%	2.00 [1.75, 4.09]	-
LiC	233	476	489	1592	2.0%	2 16 [1 76 2 67]	-
LIK	2	25	3	58	0.5%	1.59 [0.25, 10,18]	
LiX	104	269	62	279	2.4%	2.21 [1.52, 3.21]	- <u>-</u> -
Lv Z	33	155	23	115	1.9%	1.08 [0.60, 1.97]	.
Omrani AS	52	108	248	1301	2.3%	3.94 [2.64, 5.89]	· · ·
Shabrawishi M	3	16	29	105	0.8%	0.60 [0.16, 2.28]	
Shahriarirad R	5	11	17	102	0.8%	4.17 [1.14, 15.23]	
Shi S	49	82	78	334	2.1%	4.87 [2.93, 8.11]	
Wan S	4	40	9	95	0.9%	1.06 [0.31, 3.67]	
Wang D	21	36	22	102	1.5%	5.09 [2.26, 11.48]	
Wang W	8	59	36	362	1.5%	1.42 [0.63, 3.23]	
Wang Y	11	29	37	187	1.4%	2.48 [1.08, 5.69]	
Wang Z	5	14	4	55	0.7%	7.08 [1.59, 31.54]	
Wei Y	8	14	39	262	1.0%	7.62 [2.51, 23.18]	
Xiong J	20	20	19	171	1.0%	1.90 [0.93, 4.23]	
Zhang G	26	29	28	166	1.4%	4 42 [2 27 8 61]	
Zhang JJ	20	58	20	82	1.6%	1 89 [0 91 3 94]	— —
Subtotal (95% CI)		3650	20	15707	52.4%	2.46 [1.94, 3.11]	•
Total events	1425		2827				
Heterogeneity: Tau ² =	0.32; Chi ²	= 181.4	6, df = 33	8 (P < 0.	00001); l²	= 82%	
Test for overall effect:	Z = 7.50 (I	P < 0.00	001)				
2.1.2 Non-Asian studi	ies						
Argenziano MG	158	236	367	614	2.5%	1.36 [0.99, 1.87]	
Buckner FS	30	51	32	54	1.5%	0.98 [0.45, 2.14]	
Cattelan AM	50	69	103	234	1.9%	3.35 [1.86, 6.03]	
Garibaldi BT	71	171	229	523	2.5%	0.91 [0.64, 1.29]	
Giustino G	130	190	51	115	2.2%	2.72 [1.69, 4.39]	
Gregoriano C	19	35	37	64	1.4%	0.87 [0.38, 1.99]	
Israelsen SB	11	27	62	148	1.4%	0.95 [0.41, 2.20]	
Jourdes A	19	50	85	213	1.8%	0.92 [0.49, 1.74]	
Kaeuffer C	231	424	317	621	2.7%	1.15 [0.90, 1.47]	† -
Lombardi CM	182	278	168	336	2.5%	1.90 [1.37, 2.63]	
Initiation of the second secon	21	49	24	92	1.6%	2.13 [1.02, 4.42]	
Pellaud C	10	29	35	111	1.4%	1.14 [0.48, 2.71]	
Petrilli CM	680	49	1012	14/	1.0%	0.70 [0.39, 1.45]	
Popov GT	32	990	37	05	1 5%	4 56 12 05 10 141	
Raad M	333	390	409	630	2.5%	3 16 [2 28 4 37]	
Reiley M	177	314	1054	1940	2.7%	1.09 [0.85, 1.38]	 - -
Samuels S	109	147	209	346	2.3%	1.88 [1.23, 2.88]	
Schönfeld D	2763	5652	14128	41703	2.9%	1.87 [1.77, 1.97]	•
Stefan G	13	15	17	22	0.5%	1.91 [0.32, 11.47]	<u> </u>
Sulejmani A	77	136	16	37	1.6%	1.71 [0.82, 3.57]	+
Suleyman G	111	141	147	214	2.1%	1.69 [1.03, 2.77]	—
Turcotte JJ	35	48	42	69	1.5%	1.73 [0.78, 3.85]	+
Yazdanpanah Y	31	70	42	173	1.9%	2.48 [1.38, 4.45]	
Subtotal (95% CI)	_	9604		50240	47.6%	1.60 [1.37, 1.86]	
Total events	5320	- 04 05	18715	(D - C -	00041	700/	
Heterogeneity: Tau ² =	U.U8; Chi ² Z = 5.97 (I	= 94.99 P < 0.00	9, af = 23	(P < 0.0	0001); l² =	10%	
	L = 0.87 (1	- 0.00					
Total (95% CI)		13254		65947	100.0%	2.01 [1.75, 2.32]	♦
Total events	6745		21542				
Heterogeneity: Tau ² =	0.18; Chi ²	= 354.5	60, df = 57	7 (P < 0.	00001); l²	= 84%	-+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Test for overall effect:	Z = 9.73 (I	P < 0.00	001)				Favours [Non-severe] Favours [Severe]
lest for subgroup diffe	rences: C	ni² = 9.0	1, df = 1	(P = 0.0)	U3), I ² = 89	9.0%	

FIGURE 2 Forest plot for the ORs for comparing hypertension between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

	Seve	ere	Non-se	vere		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
2.2.1 Asian studies							
Abohamr SI	202	352	154	416	2.8%	2.29 [1.71, 3.06]	
Algahtani AM	29	47	33	411	1.7%	18.45 [9.28, 36,70]	
Bastug A	35	46	48	145	1.6%	6.43 [3.01, 13.76]	
Cao J	14	107	12	91	1.4%	0.99 [0.43, 2.27]	
Cao Z	3	27	.2	53	0.5%	2 08 [0 39 11 10]	
Du RH	18	51	16	58	1.4%	1 43 [0 63 3 23]	
Guan W/I	20	172	52	026	2.20/	2 19 [1 05 5 10]	
Guar WJ	20	50	20	170	2.2/0	1 00 [0.92, 4 29]	
Guner R	10	50	20	172	1.4%	1.90 [0.62, 4.36]	
Guo I	10	52	12	135	1.4%	4.56 [1.98, 10.51]	
Hong KS	3	13	6	85	0.6%	3.95 [0.85, 18.32]	
Huang C	1	13		28	0.3%	0.25 [0.03, 2.28]	
Huang R	8	23	11	179	1.1%	8.15 [2.84, 23.34]	
Khamis F	11	24	9	39	1.0%	2.82 [0.94, 8.43]	
Khan A	16	77	57	571	1.9%	2.37 [1.28, 4.37]	
Lee JY	33	137	48	557	2.2%	3.36 [2.06, 5.50]	
Lee SG	264	927	593	6412	3.1%	3.91 [3.31, 4.61]	-
Li C	90	476	202	1592	2.8%	1.60 [1.22, 2.11]	
LIK	7	25	0	58	0.2%	47.43 [2.58, 870.76]	
Li X	52	269	31	279	2.3%	1.92 [1.19, 3.10]	
Lv Z	18	155	9	115	1.4%	1.55 [0.67, 3.58]	
Omrani AS	52	108	275	1301	2.5%	3.46 [2.32, 5,17]	
Shabrawishi M	7	16	20	105	1.0%	3 31 [1 10 9 94]	
Shahriarirad R	3	11	13	102	0.7%	2 57 [0 60 10 93]	
Shi S	20	82	40	334	1 9%	2 37 [1 30 4 33]	
Tabata S	20	22	-10	12	0.2%	1 56 [0 00 25 02]	
WanS	0	20	2	40	0.2 /0	8 00 [2 27 34 00]	
Wang D	9	40	5	102	0.7 %	4.57 [1.46 14.39]	
	0	30	10	102	0.9%	4.37 [1.40, 14.20]	
Wang W	3	59	10	302	0.0%	1.69 [0.50, 7.06]	
vvang Y	/	29	23	187	1.2%	2.27 [0.87, 5.90]	-
Wang Z	6	14	1	55	0.3%	40.50 [4.30, 381.74]	
Wei Y	2	14	12	262	0.6%	3.47 [0.70, 17.29]	
Xiong F	5	30	25	101	1.0%	0.61 [0.21, 1.76]	<u></u>
Xiong S	11	55	8	61	1.1%	1.66 [0.61, 4.48]	
Yang L	4	29	17	171	0.9%	1.45 [0.45, 4.66]	
Zhang G	7	55	15	166	1.2%	1.47 [0.57, 3.81]	
Zhang JJ	8	58	9	82	1.1%	1.30 [0.47, 3.59]	
Subtotal (95% CI)		3708		15851	47.4%	2.70 [2.16, 3.37]	•
Total events	1011		1802				
Heterogeneity: Tau ² =	0.24; Chi ²	= 121.19	df = 35 (P < 0.00	0001); l ² =	71%	
Test for overall effect:	Z = 8.70 (I	< 0.000	01)				
	•		,				
2 2 2 Non-Asian stud							
And Hon-Asian staa	ies						
Argenziano MG	ies 101	236	232	614	2.8%	1 23 [0 91 1 67]	<u> </u>
Argenziano MG	ies 101 18	236	232	614 54	2.8%	1.23 [0.91, 1.67] 1 19 [0 53 2 67]	<u> </u>
Argenziano MG Buckner FS	ies 101 18 22	236 51	232 17	614 54	2.8% 1.4%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21]	
Argenziano MG Buckner FS Cattelan AM	ies 101 18 22	236 51 69	232 17 49	614 54 234	2.8% 1.4% 1.9%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.8 [0.71, 1.97]	
Argenziano MG Buckner FS Cattelan AM Filardo TD	ies 101 18 22 47	236 51 69 135	232 17 49 42	614 54 234 135	2.8% 1.4% 1.9% 2.2%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT	ies 101 18 22 47 57	236 51 69 135 171	232 17 49 42 147	614 54 234 135 523	2.8% 1.4% 1.9% 2.2% 2.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G	ies 101 18 22 47 57 80	236 51 69 135 171 190	232 17 49 42 147 34	614 54 234 135 523 115	2.8% 1.4% 1.9% 2.2% 2.6% 2.2%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C	ies 101 18 22 47 57 80 80	236 51 69 135 171 190 35	232 17 49 42 147 34 14	614 54 234 135 523 115 64	2.8% 1.4% 1.9% 2.2% 2.6% 2.2% 1.1%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB	ies 101 18 22 47 57 80 8 8 8 8	236 51 69 135 171 190 35 27	232 17 49 42 147 34 14 38	614 54 234 135 523 115 64 148	2.8% 1.4% 1.9% 2.2% 2.6% 2.2% 1.1% 1.3%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A	ies 101 18 22 47 57 80 8 8 8 8 11	236 51 69 135 171 190 35 27 50	232 17 49 42 147 34 14 38 41	614 54 234 135 523 115 64 148 213	2.8% 1.4% 1.9% 2.2% 2.6% 2.2% 1.1% 1.3% 1.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C	ies 101 18 22 47 57 80 8 8 8 11 116	236 51 69 135 171 190 35 27 50 424	232 17 49 42 147 34 14 38 41 148	614 54 234 135 523 115 64 148 213 621	2.8% 1.4% 1.9% 2.2% 2.6% 2.2% 1.1% 1.3% 1.6% 2.8%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM	ies 101 18 22 47 57 80 8 8 8 11 116 82	236 51 69 135 171 190 35 27 50 424 278	232 17 49 42 147 34 14 38 41 148 66	614 54 234 135 523 115 64 148 213 621 336	2.8% 1.4% 1.9% 2.2% 2.6% 2.2% 1.1% 1.3% 1.6% 2.8% 2.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR	ies 101 18 22 47 57 80 8 8 8 8 11 116 82 12	236 51 699 135 171 190 35 27 50 424 278 49	232 17 49 42 147 34 14 38 41 148 66 14	614 54 234 135 523 115 64 148 213 621 336 92	2.8% 1.4% 1.9% 2.2% 2.6% 1.1% 1.3% 1.6% 2.8% 2.6% 1.3%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12	236 51 69 135 171 190 35 27 50 424 278 49 29	232 17 49 42 147 34 14 38 41 148 66 14 20	614 54 234 135 523 115 64 148 213 621 336 92 111	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3%	$\begin{array}{c} 1.23 & [0.91, 1.67] \\ 1.19 & [0.53, 2.67] \\ 1.77 & [0.97, 3.21] \\ 1.18 & [0.71, 1.97] \\ 1.28 & [0.88, 1.85] \\ 1.73 & [1.06, 2.84] \\ 1.06 & [0.39, 2.84] \\ 1.22 & [0.49, 3.01] \\ 1.18 & [0.56, 2.51] \\ 1.20 & [0.91, 1.60] \\ 1.71 & [1.18, 2.48] \\ 1.81 & [0.76, 4.29] \\ 3.21 & [1.33, 7.77] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 12 47773	236 51 69 135 171 190 35 27 50 424 278 424 29 29 132197	232 17 49 42 147 34 14 38 41 148 66 14 20 1393	614 54 234 135 523 115 64 148 213 621 336 92 111 4531	2.8% 1.4% 1.9% 2.2% 2.6% 1.1% 1.3% 2.8% 2.8% 2.8% 1.3% 1.3% 3.2%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C	ies 101 18 22 47 57 80 8 8 11 116 82 12 12 12 47773 11	236 51 69 135 171 190 35 27 50 424 278 49 29 29 132197 49	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147	2.8% 1.4% 2.2% 2.2% 1.1% 1.3% 2.6% 1.3% 1.3% 3.2% 1.5%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.33, 7.77] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 389	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 3.1%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 11 389 5	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43	232 17 49 42 147 34 14 38 41 148 66 61 14 20 1393 41 561 7 7	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95	2.8% 1.4% 1.9% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 1.3% 3.2% 3.1% 0.9%	$\begin{array}{c} 1.23 & [0.91, 1.67] \\ 1.19 & [0.53, 2.67] \\ 1.77 & [0.97, 3.21] \\ 1.18 & [0.71, 1.97] \\ 1.28 & [0.88, 1.85] \\ 1.73 & [1.06, 2.84] \\ 1.06 & [0.39, 2.84] \\ 1.22 & [0.49, 3.01] \\ 1.18 & [0.56, 2.51] \\ 1.20 & [0.91, 1.60] \\ 1.71 & [1.18, 2.48] \\ 1.81 & [0.76, 4.29] \\ 3.21 & [1.33, 7.77] \\ 1.27 & [1.20, 1.36] \\ 0.75 & [0.35, 1.60] \\ 1.36 & [1.16, 1.60] \\ 1.65 & [0.49, 5.54] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 47773 11 389 5 191	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 7 261	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630	2.8% 1.4% 2.2% 2.6% 2.2% 1.3% 2.6% 1.3% 2.6% 1.3% 1.3% 3.2% 3.1% 0.9%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.6, 1.60] \\ 1.65 \ [0.49, 5.54] \\ 1.36 \ [1.05, 1.75] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 11 389 5 191 72	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.6% 1.3% 2.6% 1.3% 3.2% 3.1% 0.9% 2.9%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.05, 1.75] \\ 1.29 \ [0.97, 1.72] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 1389 5 191 72 60	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113	614 54 234 135 523 115 64 148 213 336 92 111 4531 147 1739 95 630 1940 346	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 3.1% 0.9% 2.9% 2.9% 2.5%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.05, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.21 \ [0.97, 1.72] \\ 1.21 \ [0.97, 1$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D	ies 101 18 22 47 57 80 8 8 8 8 11 116 82 12 47773 11 389 5 191 72 60 1581	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652	232 17 49 42 147 34 14 38 41 148 66 61 14 20 1393 41 561 7 261 364 113	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940 340 41703	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 3.1% 0.9% 2.9% 2.8% 2.8% 2.8%	$\begin{array}{c} 1.23 & [0.91, 1.67] \\ 1.19 & [0.53, 2.67] \\ 1.77 & [0.97, 3.21] \\ 1.18 & [0.71, 1.97] \\ 1.28 & [0.88, 1.85] \\ 1.73 & [1.06, 2.84] \\ 1.06 & [0.39, 2.84] \\ 1.22 & [0.49, 3.01] \\ 1.18 & [0.56, 2.51] \\ 1.20 & [0.91, 1.60] \\ 1.71 & [1.18, 2.48] \\ 1.81 & [0.76, 4.29] \\ 3.21 & [1.33, 7.77] \\ 1.27 & [1.20, 1.36] \\ 0.75 & [0.35, 1.60] \\ 1.36 & [1.16, 1.60] \\ 1.36 & [1.05, 1.75] \\ 1.29 & [0.97, 1.72] \\ 1.42 & [0.97, 1.72] \\ 1.42 & [0.95, 2.12] \\ 1.49 & [1.77, 2.01] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Peltrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 515	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 364 113 7118 7 7 261 364	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940 346 41703 346	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.6% 1.3% 3.2% 1.5% 3.1% 0.9% 2.8% 2.5% 3.2% 0.7%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06 \ 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18 \ 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.65 \ [0.49, 5.54] \\ 1.36 \ [1.05, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.43 \ [0.76, 2.61] \\ 1.65 \ [1.77] \\ 1.27 \ [1.27, 2.01] \\ 1.43 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61] \\ 1.44 \ [0.76, 2.61]$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Suleimani A	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 47773 11 389 5 191 72 60 1581 6 20	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 41 13 364 41 7 7 261 364 7 7 261 364	614 54 234 135 523 115 64 148 213 336 92 111 4531 4531 147 1739 95 630 1940 346 41703 222	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.6% 1.3% 3.2% 3.1% 0.9% 2.9% 2.5% 3.2% 0.7%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.49 \ [1.77, 2.01] \\ 1.43 \ [0.56, 5.61] \\ 1.40 \ [0.53, 3.69] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A	ies 101 18 22 477 57 80 8 8 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6 29 7	236 51 69 135 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15 136	232 17 49 42 147 34 14 38 41 148 66 14 200 1393 41 561 7 261 364 113 7118 7 6	614 54 234 135 523 115 64 148 213 362 1336 92 1111 4531 147 1739 95 630 1940 346 41703 22 37	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 0.9% 2.8% 2.9% 2.8% 2.5% 3.2% 0.7% 1.2%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.27, 1.20] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.71] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.89 \ [1.77, 2.01] \\ 1.43 \ [0.36, 5.61] \\ 1.40 \ [0.35, 3.68] \\ 1.69 \ [1.40, 2.60] \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G	ies 101 18 22 47 57 80 8 8 8 8 11 116 82 12 12 12 47773 11 389 5 191 72 60 1581 6 29 73 30 1581 158 10 10 10 10 10 10 10 10 10 10	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15 136 141	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 364 113 7 261 364 113 7 6 83	614 54 234 135 523 115 64 148 213 336 92 111 4531 14531 14531 14531 1739 95 630 1940 346 41703 22 37 214	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 1.3% 3.2% 2.9% 2.9% 2.8% 2.9% 3.2% 0.7% 1.2% 2.4%	$\begin{array}{c} 1.23 & [0.91, 1.67] \\ 1.19 & [0.53, 2.67] \\ 1.77 & [0.97, 3.21] \\ 1.18 & [0.71, 1.97] \\ 1.28 & [0.88, 1.85] \\ 1.73 & [1.06, 2.84] \\ 1.06 & [0.39, 2.84] \\ 1.22 & [0.49, 3.01] \\ 1.18 & [0.56, 2.51] \\ 1.20 & [0.91, 1.60] \\ 1.71 & [1.18, 2.48] \\ 1.81 & [0.76, 4.29] \\ 3.21 & [1.33, 7.77] \\ 1.27 & [1.20, 1.36] \\ 0.75 & [0.35, 1.60] \\ 1.36 & [1.16, 1.60] \\ 1.65 & [0.49, 5.54] \\ 1.36 & [1.05, 1.75] \\ 1.29 & [0.97, 1.72] \\ 1.42 & [0.95, 2.12] \\ 1.89 & [1.77, 2.01] \\ 1.43 & [0.36, 5.61] \\ 1.40 & [0.53, 3.68] \\ 1.69 & [1.10, 2.60] \\ 2.07 & [4.24, 2.52] \\ \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ	ies 101 18 22 47 57 80 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6 29 73 28 8	236 51 69 135 171 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 136 141 48	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 364 113 7118 7 6 83 818	614 54 234 135 523 115 64 148 213 621 336 92 111 147 1739 95 630 1940 346 41703 22 37 214 69	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 1.5% 3.1% 0.9% 2.8% 2.5% 3.2% 0.7% 2.8% 2.5% 3.2% 0.7% 2.4% 2.5% 2.6% 2.4% 2.5% 2.6% 2.6% 2.6% 2.2% 2.5% 2.2% 2.5% 2.2% 2.5% 2.2% 2.5% 2.2% 2.5% 2.5	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.65 \ [0.49, 5.54] \\ 1.36 \ [1.05, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.42 \ [0.95, 2.12] \\ 1.43 \ [0.56, 5.61] \\ 1.40 \ [0.53, 3.68] \\ 1.69 \ [1.10, 2.60] \\ 3.97 \ [1.81, 8.71] \\ 4.9 \ [0.77 \ [1.81, 8.71] \\ 4.9 \ [0.77 \ [1.81, 8.71] \\ 1.9 \ [1.81, 8.71] \\ 1.9 \ [1.81, 8.71] \\ $	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subatel (SC)	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 47773 11 389 5 191 73 80 1581 6 29 73 28 13	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 49 990 43 390 314 147 5652 15 136 141 48 69	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 318 26	614 54 234 135 523 115 64 148 213 362 111 4531 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.6% 1.3% 3.2% 3.1% 0.9% 2.9% 2.5% 3.2% 0.7% 1.2% 2.4% 2.5% 3.2%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.36 \ [1.16, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.43 \ [0.53, 3.68] \\ 1.69 \ [1.10, 2.60] \\ 3.97 \ [1.81, 8.71] \\ 1.33 \ [0.64, 2.77] \\ 1.31 \ [0.67] \\ 1.41 \ [0.57] \\ 1.41 \ [0.57] \\ 1.41 \ [0.57] \\ 1.42 \ [0.57] \\ 1.43 \ [0.46, 2.77] \\ 1.43 \ [0.46, 2.77] \\ 1.44 \ [0.57] \\ 1.44 \ [0.57] \\ 1.44 \ [0.57] \\ 1.45 \ [0.46, 2.77] \\ 1.44 \ [0.57] \\ 1.45 \ [0.46, 2.77] \\ 1.45 \ [0.46, 2.77] \\ 1.46 \ [0.57] \\ 1.46 \ [0.57] \\ 1.40 \ [0.56] \\ 1.50 \ [1.10, 2.60] \\ 3.97 \ [1.81, 8.71] \\ 1.33 \ [0.64, 2.77] \\ 1.41 \ [0.57] \ [0.57] \\ 1.41 \ [0.57] \ [0.57] \\ 1.41 \ [0.57] \ $	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI)	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6 29 73 28 13	236 51 69 135 27 50 424 278 49 29 132197 49 990 43 390 314 7 5652 15 136 141 48 69 141935	232 17 49 42 147 34 14 38 41 148 66 14 200 1393 41 561 7 261 364 113 7118 7 6 83 83 18 826	614 54 234 135 523 115 64 148 213 336 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175 54908	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 0.9% 2.8% 2.9% 2.8% 2.2% 0.7% 1.2% 2.4% 1.5% 1.6% 52.6%	$\begin{array}{c} 1.23 \ [0.91, 1.67]\\ 1.19 \ [0.53, 2.67]\\ 1.77 \ [0.97, 3.21]\\ 1.18 \ [0.71, 1.97]\\ 1.28 \ [0.88, 1.85]\\ 1.73 \ [1.06, 2.84]\\ 1.06 \ [0.39, 2.84]\\ 1.22 \ [0.49, 3.01]\\ 1.18 \ [0.56, 2.51]\\ 1.20 \ [0.91, 1.60]\\ 1.71 \ [1.18, 2.48]\\ 1.81 \ [0.76, 4.29]\\ 3.21 \ [1.33, 7.77]\\ 1.27 \ [1.20, 1.36]\\ 0.75 \ [0.35, 1.60]\\ 1.36 \ [1.16, 1.60]\\ 1.36 \ [1.16, 1.60]\\ 1.36 \ [1.16, 1.60]\\ 1.36 \ [1.05, 1.75]\\ 1.29 \ [0.97, 1.72]\\ 1.42 \ [0.95, 2.12]\\ 1.89 \ [1.77, 2.01]\\ 1.43 \ [0.36, 5.61]\\ 1.40 \ [0.53, 3.68]\\ 1.69 \ [1.10, 2.60]\\ 3.97 \ [1.81, 8.71]\\ 1.33 \ [0.64, 2.77]\\ 1.44 \ [1.27, 1.63]\\ \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI)	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 12 47773 11 389 5 191 72 60 0 1581 6 29 73 28 13 50805	236 51 69 135 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15 136 141 48 69 9141935	232 17 49 42 147 34 14 38 41 14 8 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 18 26	614 54 234 135 523 115 64 148 213 362 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 215 54908	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 1.3% 3.1% 0.9% 2.8% 2.8% 2.8% 2.8% 2.2% 0.7% 1.2% 2.4% 1.2% 2.4% 52.6%	$\begin{array}{c} 1.23 \ [0.91, \ 1.67] \\ 1.19 \ [0.53, \ 2.67] \\ 1.77 \ [0.97, \ 3.21] \\ 1.18 \ [0.71, \ 1.97] \\ 1.28 \ [0.88, \ 1.85] \\ 1.73 \ [1.06, \ 2.84] \\ 1.06 \ [0.39, \ 2.84] \\ 1.22 \ [0.49, \ 3.01] \\ 1.22 \ [0.49, \ 3.01] \\ 1.22 \ [0.49, \ 3.01] \\ 1.22 \ [0.49, \ 3.01] \\ 1.20 \ [0.91, \ 1.60] \\ 1.71 \ [1.18, \ 2.48] \\ 1.81 \ [0.76, \ 4.29] \\ 3.21 \ [1.33, \ 7.77] \\ 1.27 \ [1.20, \ 1.36] \\ 0.75 \ [0.35, \ 1.60] \\ 1.36 \ [1.16, \ 1.60] \\ 1.36 \ [1.16, \ 1.60] \\ 1.36 \ [1.05, \ 1.75] \\ 1.29 \ [0.97, \ 1.72] \\ 1.42 \ [0.95, \ 2.12] \\ 1.42 \ [0.95, \ 2.12] \\ 1.43 \ [0.36, \ 5.61] \\ 1.40 \ [0.53, \ 3.68] \\ 1.69 \ [1.10, \ 2.60] \\ 3.97 \ [1.81, \ 8.71] \\ 1.33 \ [0.64, \ 2.77] \\ 1.44 \ [1.27, \ 1.63] \\ \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Peltilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events	ies 101 18 22 47 57 80 8 8 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6 29 73 28 13 50805 0.04; Chi ²	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5655 136 141 48 69 141935 = 98.98,	232 17 49 42 147 34 14 38 41 14 38 41 1393 41 561 364 113 7 261 364 113 7 6 83 8 26 10860 df = 25 (F	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175 54908	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 1.3% 1.5% 3.2% 0.7% 2.8% 2.5% 3.2% 0.7% 2.8% 2.5% 3.2% 0.7% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06, 2.84] \\ 1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.65 \ [0.49, 5.54] \\ 1.36 \ [1.05, 1.75] \\ 1.29 \ [0.97, 1.72] \\ 1.42 \ [0.95, 2.12] \\ 1.43 \ [0.36, 5.61] \\ 1.40 \ [0.53, 3.68] \\ 1.69 \ [1.10, 2.60] \\ 3.97 \ [1.81, 8.71] \\ 1.33 \ [0.64, 2.77] \\ 1.44 \ [1.27, 1.63] \\ \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeulfer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events	ies 101 18 22 47 57 80 8 8 11 116 82 12 47773 11 389 5 191 72 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I	236 51 69 135 171 190 35 27 50 50 424 278 49 29 132197 49 990 43 390 314 49 990 43 390 314 147 5652 15 136 141 48 69 141935 = 98.98, > < 0.000	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 318 26 10860 df = 25 (F 01)	614 54 234 1355 523 115 64 148 213 362 92 111 4531 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175 54908	2.8% 1.4% 2.2% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 1.3% 3.2% 3.1% 0.9% 2.9% 2.8% 2.5% 3.2% 0.7% 1.5% 1.6% 52.6%	$\begin{array}{c} 1.23 \ [0.91, 1.67] \\ 1.19 \ [0.53, 2.67] \\ 1.77 \ [0.97, 3.21] \\ 1.18 \ [0.71, 1.97] \\ 1.28 \ [0.88, 1.85] \\ 1.73 \ [1.06 \ [0.39, 2.84] \\ 1.22 \ [0.49, 3.01] \\ 1.22 \ [0.49, 3.01] \\ 1.18 \ [0.56, 2.51] \\ 1.20 \ [0.91, 1.60] \\ 1.71 \ [1.18, 2.48] \\ 1.81 \ [0.76, 4.29] \\ 3.21 \ [1.33, 7.77] \\ 1.27 \ [1.20, 1.36] \\ 0.75 \ [0.35, 1.60] \\ 1.36 \ [1.16, 1.60] \\ 1.65 \ [0.49, 5.54] \\ 1.36 \ [1.09, 5.54] \\ 1.36 \ [1.09, 5.212] \\ 1.42 \ [0.95, 2.12] \\ 1.42 \ [0.95, 2.12] \\ 1.42 \ [0.95, 2.12] \\ 1.43 \ [0.56, 5.61] \\ 1.69 \ [1.10, 2.60] \\ 3.97 \ [1.81, 8.71] \\ 1.33 \ [0.64, 2.77] \\ 1.44 \ [1.27, 1.63] \\ \end{array}$	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	lies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 11 389 5 191 72 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15 136 141 48 69 141935 = 98.98, 2 < 0.000	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 83 18 26 10860 df = 25 (F 01)	614 54 234 135 523 115 64 148 213 3621 336 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175 54908	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 1.3% 2.8% 2.6% 1.3% 3.2% 0.9% 2.9% 2.8% 3.2% 0.7% 1.2% 2.5% 3.2% 0.7% 1.2% 2.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.33, 7.77] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60] 1.36 [1.16, 1.60] 1.36 [1.05, 1.75] 1.29 [0.97, 1.72] 1.42 [0.95, 2.12] 1.89 [1.77, 2.01] 1.43 [0.36, 5.61] 1.40 [0.53, 3.68] 1.69 [1.10, 2.60] 3.97 [1.81, 8.71] 1.33 [0.64, 2.77] 1.44 [1.27, 1.63]	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Sulegman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 47773 389 5 191 72 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I	236 51 69 135 27 50 424 278 49 29 132197 49 990 43 390 314 137 5652 15 136 141 48 69 141935 = 98.98, > < 0.000 145643	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 37118 7 6 83 118 7 6 83 126 10860 df = 25 (F 01)	614 54 234 135 523 115 64 148 213 362 1336 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 9 175 54908 2 < 0.000 70759	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 0.9% 2.8% 2.5% 3.2% 0.7% 1.2% 2.4% 1.2% 2.4% 1.6% 52.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.37, 7.7] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60] 1.36 [1.16, 1.60] 1.36 [1.16, 1.60] 1.36 [1.05, 1.75] 1.29 [0.97, 1.72] 1.42 [0.95, 2.12] 1.89 [1.77, 2.01] 1.43 [0.36, 5.61] 1.40 [0.53, 3.68] 1.69 [1.10, 2.60] 3.97 [1.81, 8.71] 1.33 [0.64, 2.77] 1.44 [1.27, 1.63] 75%	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 12 12 47773 11 389 5 191 72 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I	236 51 69 135 171 190 35 27 50 424 278 49 29 132197 49 990 43 390 314 147 5652 15 136 141 48 69 9 141935 = 98.98, 0 < 0.000 145643	232 17 49 42 147 34 14 38 41 148 66 61 14 200 1393 41 561 364 113 7118 7 6 83 18 26 10860 df = 25 (F 01) 12662	614 54 234 135 523 115 64 148 213 362 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 5 54908 2 < 0.000 70759	2.8% 1.4% 2.2% 2.6% 2.2% 1.3% 2.8% 2.6% 1.3% 1.3% 1.3% 1.5% 3.1% 0.9% 2.8% 2.5% 3.2% 0.7% 2.8% 2.5% 3.2% 0.7% 2.6% 52.6%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.33, 7.77] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60] 1.36 [1.16, 1.60] 1.65 [0.49, 5.54] 1.36 [1.05, 1.75] 1.29 [0.97, 1.72] 1.42 [0.95, 2.12] 1.89 [1.77, 2.01] 1.43 [0.36, 5.61] 1.40 [0.53, 3.68] 1.69 [1.10, 2.60] 3.97 [1.81, 8.71] 1.33 [0.64, 2.77] 1.44 [1.27, 1.63] 75%	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	ies 101 18 22 47 57 80 8 8 11 116 82 12 12 47 77 389 5 191 172 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I 51816 0.14; Chi ²	236 51 69 135 171 190 35 27 50 50 424 278 49 990 43 390 314 147 5652 15 136 141 147 5652 15 136 141 48 69 141935 = 98.98, > < 0.000 145643 = 367.68	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 18 26 10860 df = 25 (F 01) 126622 , df = 61 of	614 54 234 1355 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940 346 41703 22 37 214 69 175 54908 2<0.000 (P < 0.00)	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 1.3% 1.5% 3.2% 0.9% 2.9% 2.8% 2.5% 3.2% 0.7% 1.2% 1.5% 1.6% 52.6% 0.1); l ² = 7 100.0%	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.33, 7.77] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60] 1.36 [1.16, 1.60] 1.65 [0.49, 5.54] 1.36 [1.05, 1.75] 1.29 [0.97, 1.72] 1.42 [0.95, 2.12] 1.89 [1.77, 2.01] 1.43 [0.36, 5.61] 1.40 [0.53, 3.68] 1.69 [1.10, 2.60] 3.97 [1.81, 8.71] 1.33 [0.64, 2.77] 1.44 [1.27, 1.63] 75%	
Argenziano MG Buckner FS Cattelan AM Filardo TD Garibaldi BT Giustino G Gregoriano C Israelsen SB Jourdes A Kaeuffer C Lombardi CM Matangila JR Ortiz-Brizuela E Oud L Pellaud C Petrilli CM Popov GT Raad M Reilev M Samuels S Schönfeld D Stefan G Sulejmani A Suleyman G Turcotte JJ Yazdanpanah Y Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	ies 101 18 22 47 57 80 8 8 8 11 116 82 12 47773 11 389 5 191 72 2 60 1581 6 29 73 28 13 50805 0.04; Chi ² Z = 5.75 (I 51816 0.14; Chi ² Z = 9.95 (I	236 51 69 135 171 190 35 27 5424 278 49 29 132197 49 990 43 390 314 147 5652 15 136 1417 5652 15 136 141 48 69 141935 = 98.98, 5 < 0.000 145643 = 367.68	232 17 49 42 147 34 14 38 41 148 66 14 20 1393 41 561 7 261 364 113 7118 7 6 83 318 26 10860 cf = 25 (F 01) 126622 , df = 61 (01)	614 54 234 135 523 115 64 148 213 621 336 92 111 4531 147 1739 95 630 1940 1940 346 41703 22 37 214 69 175 54908 2 < 0.000 (P < 0.00)	2.8% 1.4% 1.9% 2.6% 2.2% 1.1% 1.3% 2.8% 2.6% 1.3% 3.2% 1.5% 3.1% 0.9% 2.9% 2.5% 3.2% 0.7% 1.2% 2.5% 3.2% 0.7% 1.5% 1.6% 52.6% 0.01); l ² = 7	1.23 [0.91, 1.67] 1.19 [0.53, 2.67] 1.77 [0.97, 3.21] 1.18 [0.71, 1.97] 1.28 [0.88, 1.85] 1.73 [1.06, 2.84] 1.06 [0.39, 2.84] 1.22 [0.49, 3.01] 1.18 [0.56, 2.51] 1.20 [0.91, 1.60] 1.71 [1.18, 2.48] 1.81 [0.76, 4.29] 3.21 [1.33, 7.77] 1.27 [1.20, 1.36] 0.75 [0.35, 1.60] 1.36 [1.16, 1.60] 1.36 [1.16, 1.60] 1.36 [1.05, 1.75] 1.29 [0.97, 1.72] 1.42 [0.95, 2.12] 1.89 [1.77, 2.01] 1.43 [0.36, 5.61] 1.60 [1.10, 2.60] 3.97 [1.81, 8.71] 1.33 [0.64, 2.77] 1.44 [1.27, 1.63] 75%	0.02 0.1 Eavours [Several]

FIGURE 3 Forest plots depict the comparison of diabetes between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

```
_NursingOpen
```

-WILEY / 743

	Severe	Non-se	vere		Odds Ratio	Odds Ratio
Study or Subgroup	Events Tota	al Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
2.3.1 Asian studies						
Abohamr SI	47 35	2 35	416	3.0%	1.68 [1.06, 2.66]	
Alqahtani AM	3 4	7 6	411	1.4%	4.60 [1.11, 19.05]	
Bastug A	28 4	6 31	145	2.5%	5.72 [2.80, 11.67]	
Cao Z	5 2	7 5	53	1.5%	2.18 [0.57, 8.32]	
Guan WJ	10 17	3 17	926	2.3%	3.28 [1.48, 7.29]	
Guner R	20 5	0 36	172	2.6%	2.52 [1.28, 4.94]	
Guo I	25 5	2 4	135	1.7%	30.32 [9.76, 94.24]	
Hong KS	0 1	3 11 2 2	80	0.5%	0.24 [0.01, 4.32]	
Huang C Huang P	3 1	3 3 1	170	0.7%	2.50 [0.43, 14.54]	
	6 13	7 11	557	1.9%	2 27 [0.83 6 26]	
Lee SG	155 92	7 300	6412	3.3%	4 09 [3 32 5 04]	
LiC	68 47	6 114	1592	3.2%	2 16 [1 57 2 97]	
LiX	28 26	9 6	279	2.1%	5.29 [2.15, 12.98]	
Lv Z	7 15	5 5	115	1.7%	1.04 [0.32, 3.37]	
Omrani AS	10 10	8 31	1301	2.4%	4.18 [1.99, 8.78]	
Shabrawishi M	3 1	6 5	105	1.2%	4.62 [0.99, 21.61]	·
Shahriarirad R	4 1	1 12	102	1.4%	4.29 [1.09, 16.84]	
Shi S	36 8	2 25	334	2.7%	9.67 [5.33, 17.57]	
Tabata S	11 2	8 11	43	1.9%	1.88 [0.68, 5.23]	
Wan S	6 4	0 1	95	0.8%	16.59 [1.93, 142.84]	
Wang D	93	6 11	102	2.0%	2.76 [1.03, 7.35]	
Wang Y	7 2	97	187	1.7%	8.18 [2.62, 25.51]	
Wang Z	5 1	4 3	55	1.2%	9.63 [1.95, 47.54]	
Wei Y	4 1	4 8	262	1.4%	12.70 [3.27, 49.30]	
Xiong F	25 3	0 65	101	1.9%	2.77 [0.98, 7.86]	
Xiong S	13 5	5 4	61	1.7%	4.41 [1.34, 14.49]	
Zhang G	13 5	59	166	2.1%	5.40 [2.16, 13.49]	· · ·
Zhang JJ	11 5	8 10	82	2.1%	1.69 [0.66, 4.28]	
Subtotal (95% CI)	333		14501	53.9%	3.72 [2.87, 4.81]	•
l otal events	563 0.00: 053 - 70	790		00004). 12	- 000/	
Heterogeneity: 1 au ² =	0.23; Cnr = 73	.33, at = 28	(P < 0.0	JUUU1); I*	= 62%	
rest for overall effect.	2 - 9.97 (P < 0	.00001)				
2.3.2 Non-Asian stud	es					
Argenziano MG	53 23	6 153	614	3.1%	0.87 [0.61, 1.25]	
Buckner FS	18 5	1 22	54	2.3%	0.79 [0.36, 1.75]	
Filardo TD	73 13	5 66	135	2.9%	1.23 [0.76, 1.99]	- <u>+-</u> -
Garibaldi BT	64 17	1 126	523	3.1%	1.88 [1.30, 2.73]	
Giustino G	16 18	7 6	112	2.0%	1.65 [0.63, 4.36]	
Gregoriano C	9 3	5 16	64	2.1%	1.04 [0.40, 2.67]	
Israelsen SB	14 2	7 76	148	2.3%	1.02 [0.45, 2.32]	
Jourdes A	6 5	0 29	213	2.1%	0.87 [0.34, 2.21]	
Lombardi CM	87 27	8 50	336	3.1%	2.61 [1.76, 3.86]	
		9 5 0 00	111	0.7%		
	0 4 277 00	a 20	14/	2.0%	0.08 [0.33, 2.35]	
	12 4	0 020 3 10	05	3.4% 2.1%	1.05 [1.41, 2.03] 3.20 [1.20 .0.20]	· · · · ·
Raad M	80 20	0 42	630	2.1%	3 52 [2 37 5 23]	
Reiley M	58 31	4 377	1940	3.2%	0.94 [0.69 1.28]	- -
Stefan G	12 1	5 7	22	1.2%	8.57 [1.82 40 42]	· · · · · · · · · · · · · · · · · · ·
Suleimani A	88 13	6 19	37	2.4%	1.74 [0.83, 3.62]	<u> </u>
Sulevman G	26 14	1 30	214	2.8%	1.39 [0.78, 2.46]	+
Turcotte JJ	14 4	8 12	69	2.2%	1.96 [0.81, 4.72]	+
Subtotal (95% CI)	332	5	7203	46.1%	1.52 [1.20, 1.92]	◆
Total events	914	1392				· ·
Heterogeneity: Tau ² =	0.15; Chi ² = 61	.64, df = 18	(P < 0.0	00001); l²	= 71%	
Test for overall effect:	Z = 3.46 (P = 0	.0005)	•			
Total (95% CI)	666	1	21704	100.0%	2.47 [2.00. 3.06]	•
Total events	1477	2182			,	
Heterogeneity: Tau ² =	0.34; Chi ² = 22	8.96. df = 4	7 (P < 0	.00001): 1	² = 79%	
Test for overall effect:	Z = 8.31 (P < 0	.00001)				0.02 0.1 1 10 50
Test for subgroup diffe	rences: Chi ² =	25.19, df =	1 (P < 0	.00001), I ^s	² = 96.0%	Favours [NOII-Severe] Favours [Severe]

FIGURE 4 Forest plot for the ORs for comparing cardiovascular disease between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

	Seve	ere	Non-se	vere		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl
2.4.1 Asian studies							
Alqahtani AM	1	47	1	411	0.6%	8.91 [0.55, 144.90]	
Du RH	2	51	6	58	1.5%	0.35 [0.07, 1.84]	
Guan WJ	3	173	7	926	1.9%	2.32 [0.59, 9.05]	
Guner R	3	50	6	172	1.8%	1.77 [0.43, 7.33]	
Guo T	6	52	7	135	2.4%	2.39 [0.76, 7.47]	+ · · · ·
Hong KS	1	13	3	85	0.8%	2.28 [0.22, 23.71]	· · · · · · · · · · · · · · · · · · ·
Huang C	0	13	1	28	0.5%	0.68 [0.03, 17.80]	
Huang R	0	23	2	179	0.5%	1.51 [0.07, 32.43]	
Khan A	5	77	13	571	2.6%	2.98 [1.03, 8.61]	
Lee JY	5	137	18	557	2.7%	1.13 [0.41, 3.11]	
Lee SG	60	927	102	6412	4.8%	4.28 [3.09, 5.94]	
Li C	29	476	46	1592	4.4%	2.18 [1.35, 3.51]	
Li X	14	257	10	256	3.2%	1.42 [0.62, 3.25]	-
Lv Z	0	155	2	115	0.5%	0.15 [0.01, 3.07]	· · · · · · · · · · · · · · · · · · ·
Omrani AS	2	108	18	1301	1.7%	1.34 [0.31, 5.87]	
Shabrawishi M	2	16	0	105	0.5%	36.38 [1.66, 795.99]	→
Shahriarirad R	0	11	1	102	0.5%	2.94 [0.11, 76,50]	· · · · · · · · · · · · · · · · · · ·
Shi S	7	82	2	334	1.5%	15 49 [3 16, 76 08]	
Tabata S		28	2	43	0.8%	0 76 10 07 8 79	
Wan S	3	40	1	95	0.0%	7 62 [0 77 75 63]	
Wang D	4	36	6	102	2.0%	2 00 10 53 7 541	
Wang W	-	50	4	362	0.6%		
Wang Z	1	14	4	55	0.0%		
Waily Z	1	14	2	262	0.0%	10.00 [0.85, 117.55]	· · · · · · · · · · · · · · · · · · ·
	2	14	2	202	1.20/		
Viu J Viena E	2	20	3	197	0.6%	2 45 [0.20, 9.74]	
Xiong F	1	30	1	101	0.0%		
Xiong S	4	55	0	10	0.0%	10.75 [0.57, 204.34]	
	1	29	3	1/1	0.9%	2.00 [0.20, 19.91]	
Zhang G Subtotal (05% CI)	4	2111	5	166	1.9%	2.53 [0.65, 9.76]	
Subiolal (95% CI)	400	3111	075	14334	43.370	2.51 [1.00, 5.10]	
	162	00.07	2/5	- 0.00	12 - 000/		
Heterogeneity: 1 au ² =	$0.16; Chl^2$	= 39.27, 0	at = 28 (F	9 = 0.08); I ² = 29%		
l est for overall effect:	Z = 5.17 (H	- < 0.000	01)				
2 / 2 Non Asian stud	ioc						
2.4.2 NOIT-ASIAN SLUU	les		10		4.00/	0.00 10 54 4 741	
Argenziano MG	17	236	46	614	4.0%	0.96 [0.54, 1.71]	
Buckner FS	11	51	5	54	2.4%	2.69 [0.86, 8.40]	
Cattelan AM	5	69	21	234	2.7%	0.79 [0.29, 2.19]	
Filardo TD	1	135	6	135	1.0%	0.16 [0.02, 1.35]	
Garibaldi BT	22	171	43	523	4.1%	1.65 [0.96, 2.84]	
Gregoriano C	7	35	4	64	2.0%	3.75 [1.01, 13.87]	
Jourdes A	5	50	22	213	2.6%	0.96 [0.35, 2.69]	
Kaeuffer C	44	424	65	621	4.6%	0.99 [0.66, 1.48]	
Oud L	14544	132197	651	4531	5.3%	0.74 [0.68, 0.80]	
Pellaud C	1	49	14	147	1.1%	0.20 [0.03, 1.55]	
Petrilli CM	138	990	154	1739	5.0%	1.67 [1.31, 2.13]	1 m
Popov GT	8	43	2	95	1.5%	10.63 [2.15, 52.51]	
Reilev M	57	314	317	1940	4.8%	1.14 [0.83, 1.55]	+-
Samuels S	15	147	24	346	3.7%	1.52 [0.78, 3.00]	+
Schönfeld D	403	5652	2148	41703	5.2%	1.41 [1.27, 1.58]	*
Stefan G	1	15	1	22	0.6%	1.50 [0.09, 26.01]	
Suleyman G	23	141	20	214	3.8%	1.89 [1.00, 3.59]	<u> </u>
Yazdanpanah Y	3	70	11	175	2.0%	0.67 [0.18, 2.47]	<u> </u>
Subtotal (95% CI)		140789		53370	56.5%	1.26 [0.96, 1.64]	◆
Total events	15305		3554				
Heterogeneity: Tau ² =	0.18; Chi ²	= 134.88	df = 17	(P < 0.0	0001); l² =	87%	
Test for overall effect:	Z = 1.65 (F	P = 0.10)	- 1894) A				
Total (95% CI)		143000		68334	100 0%	1 63 [1 20 2 06]	
Total (95 /0 Cl)	45407	143900	0000	00324	100.0%	1.05 [1.29, 2.00]	•
	15467	- 050 70	3829	(D 4 0 0	0004) 12	000/	
Heterogeneity: Tau ² =	0.27; Chí ²	= 258.72	, at = 46	(P < 0.0	0001); l ² =	8∠%	0.02 0.1 1 10 50
l est for overall effect:	∠ = 4.07 (F	- < 0.000	1)		A) 10	0 01	Favours [Non-severe] Favours [Severe]
Test for subgroup diffe	rences: Cl	$hi^2 = 8.27$, df = 1 (F	P = 0.00	4), I² = 87.9	9%	

FIGURE 5 Forest plots depict the ORs for comparing cancer between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

```
_NursingOpen
```

745

WILEY

	Seve	re	Non-se	vere		Odds Ratio	Odds Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Random, 95% C	M-H. Random, 95% Cl
2.5.1 Asian studies							
Cao Z	0	27	5	53	0.6%	0 16 [0 01 3 01]	· · · · · · · · · · · · · · · · · · ·
Guan W.I	6	173	6	926	2.9%	5 51 [1 76 17 29]	
Guner R	6	50	6	172	2.8%	3 77 [1 16 12 27]	
Guo T	4	52	0	135	0.6%	25 14 [1 33 475 67]	
Huang C	1	13	0	28	0.5%	6 84 [0 26 179 78]	
Lee IY	2	137	2	557	1.3%	4 11 [0 57 29 45]	
Lee SG	32	927	49	6412	6.4%	4 64 [2 96 7 29]	
	16	476	16	1592	4 9%	3 43 [1 70 6 90]	
LIK	4	25	1	58	1.0%	10 86 [1 15 102 77]	_
	13	269	4	279	2.9%	3 49 [1 12 10 85]	
	3	155	2	115	1.5%	1 12 [0 18 6 78]	
Shahrawishi M	1	16	0	105	0.5%	20 42 10 80 523 841	
Shabriarirad R	1	11	8	103	1 1%		
Shi S	6	82	6	334	2.9%	4 32 [1 35 13 75]	
Wan S	1	40	0	05	0.6%	23 55 [1 24 448 35]	→
Wang D	-	36	1	102	1.0%		· · · · · · · · · · · · · · · · · · ·
Wang W	1	50	17	362	1.0%	0.35 [0.05, 2.69]	· · · · · · · · · · · · · · · · · · ·
Wang V	י ר	14	17	502	1.270	4 42 10 56 24 57	
	2	14	2	262	1.270	4.42 [0.50, 54.57]	
	2	14	5	202	1.0%	0.07 [1.01, 40.70]	
VVU J Viena F	1	83	0	197	0.5%	7.16 [0.29, 176.12]	
	1	30	4	101	1.0%	0.84 [0.09, 7.78]	
Xiong S	1	55	0	10	0.5%	3.39 [0.14, 84.84]	
Zhang G	4	55	2	166	1.6%	6.43 [1.14, 36.14]	
Zhang JJ Subtotal (95% CI)	2	58 2857	0	12351	0.6%	7.30 [0.34, 154.96]	
Total events	110	2007	100	12551	33.070	4.04 [3.03, 3.34]	•
Total events			130	(D - 0 4	$(-1) \cdot 12 - 40/$		
Test for everall effects	J.UT; Chi ²	= 23.22	, ar = 23	(P = 0.4	5); 1- = 1%		
Test for overall effect. 2	2 - 9.70 (1	- < 0.00	001)				
2.5.2 Non-Asian studi	es						
Argenziano MG	14	236	42	614	5.3%	0.86 [0.46, 1.60]	
Buckner FS	7	51	4	54	2.5%	1.99 [0.55, 7.25]	
Garibaldi BT	28	171	95	523	6.3%	0.88 [0.56, 1.40]	
Giustino G	10	190	8	115	3.6%	0.74 [0.28, 1.94]	
Gregoriano C	4	35	4	64	2.1%	1.94 [0.45, 8.27]	
Israelsen SB	2	27	9	148	1.8%	1.24 [0.25, 6.06]	
Lombardi CM	31	278	27	336	5.8%	1.44 [0.84, 2.47]	+
Ortiz-Brizuela E	1	29	1	111	0.7%	3.93 [0.24, 64.78]	
Pellaud C	5	49	11	147	3.0%	1.40 [0.46, 4.27]	-
Petrilli CM	169	990	284	1739	7.7%	1.05 [0.86, 1.30]	+
Popov GT	3	43	1	95	1.0%	7.05 [0.71, 69.84]	
Raad M	50	390	55	630	6.7%	1.54 [1.02, 2.31]	
Schönfeld D	548	5652	2296	41703	8.1%	1.84 [1.67, 2.03]	-
Stefan G	3	15	0	22	0.6%	12.60 [0.60, 264,14]	
Suleyman G	18	141	23	214	5.1%	1 22 [0 63, 2 34]	
Subtotal (95% CI)		8297	20	46515	60.2%	1.32 [1.02, 1.70]	◆
Total events	893		2860				
Heterogeneity: Tau ² = ().10; Chi ²	= 41.16	. df = 14	(P = 0.0)	002); l ² = 6	66%	
Test for overall effect: 2	z = 2.15 (I	P = 0.03)	, 2.0	,		
T-4-1 (059/ 01)		44454		50000	400 00/	0.04 14 00. 0.043	
i otal (95% CI)	4000	11154	0000	28866	100.0%	2.04 [1.60, 2.61]	
I otal events	1009		2996			2.4%	
Heterogeneity: Tau ² = (0.19; Chi ²	= 104.8	2, df = 38	3 (P < 0.	00001); l²	= 64%	0.02 0.1 1 10 50
Test for overall effect: Z	<u>z</u> = 5.77 (F	- < 0.00	001)				Favours [Non-severe] Favours [Severe]
Test for subgroup differ	ences: Cl	$hi^2 = 33.$	89, df = 1	I (P < 0.	00001), l ²	= 97.0%	

FIGURE 6 Forest plots depict the ORs for comparing COPD between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

plots were obtained from all included studies evaluating comorbidities between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients. This visual symmetry and funnel shape suggested a low risk of publication bias.

4 | DISCUSSION

The rapid increase in the number of COVID-19 cases and death toll is having devastating social and economic consequences around



FIGURE 7 Forest plots depict the ORs for comparing chronic kidney disease between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients

the world. Early identification and timely treatment of severe cases are vitally important in resource-limited countries to save more lives with limited healthcare facilities. This systematic review and meta-analysis of comparative studies suggested that the severity of patients with COVID-19 was significantly associated with pre-existing comorbidities. To the best of our knowledge, this study is the first meta-analysis to compare the comorbidities between severe versus non-severe COVID-19 patients in Asian and non-Asian populations. We found that the incidence of hypertension, diabetes, cardiovascular disease and chronic kidney disease was significantly higher in severe compared to non-severe patients in both Asian and non-Asian group in terms of subgroup analysis.

_NursingOpen

-WILEY

Our findings are consistent with previous studies that showed a statistically significant association of pre-existing comorbidities with severe COVID-19 cases (Del Sole et al., 2020; Yang, Zheng, et al., 2020; Zhang, Lee, et al., 2020; Zhou, Yang, et al., 2020). Additionally, among Asian studies, there was a statistically significant difference between cancer and COPD incidence between severe and non-severe COVID-19 patients. However, the incidence of cancer and COPD in severe and non-severe non-Asian patients demonstrated no statistically significant difference.

Meta-analysis by Yin et al. (2021) assessed the role of comorbidity in COVID-19 progression in Chinese patients and indicated that chronic kidney disease, cardiovascular disease, cancer, diabetes and hypertension were the strongest risk factor in disease exacerbation. Besides, Yang, Zheng, et al. (2020) showed that the pooled odds ratio of hypertension, respiratory system disease and cardiovascular disease were 2.36, 2.46 and 3.42, respectively, between severe and non-severe patients. Another meta-analysis by Giri et al. (2020) concluded that incidence of hypertension, cardiovascular disease, diabetes and cancer in the severe group was statistically significant higher than non-severe group. However, in their meta-analysis, all included studies were from China. Although we could not find any meta-analysis that compared comorbidities between severe and non-severe COVID-19 patients for the non-Asian studies only; however, the result of individual studies published in non-Asian countries showed that hypertension, cardiovascular disease, diabetes and cancer incidences were higher in severe or ICU groups (Argenziano et al., 2020; Buckner et al., 2020; Cattelan et al., 2020; Ferguson et al., 2020; Filardo et al., 2020; Pellaud et al., 2020; Schönfeld et al., 2021). Our findings are in line with current knowledge that patients with comorbidities are more susceptible to severe infection.

Pre-existing cardiovascular disease and cardiovascular risk factors such as hypertension and diabetes enhance vulnerability to COVID-19 as the SARS-CoV-2 enters lung cells via the ACE2 receptor (Ni et al., 2020). Furthermore, COVID-19 may induce direct myocardial injury by upregulation of angiotensin-converting enzyme (Zheng et al., 2020). Additionally, renin-aldosterone-angiotensin system (RAAS) plays a vital role in the pathogenesis of COVID-19 and Tignanelli et al. (2020) revealed that hypertensive patients have hyperactive RAAS activation through angiotensin-2, which may lead to acute lung injury during SARS-CoV-2 virus infection. Previous studies (Al-Salameh et al., 2021; Zhou et al., 2021) have demonstrated that patients with diabetes were associated with significantly higher risk of suffering from severe COVID-19 confirming that inflammation is important in the pathogenesis of severe COVID-19. Due to weakened immune systems, people with cancer are considered as a highly vulnerable group for COVID-19. This was further supported by study by Liang et al. (2020) as people with cancer were at increased risk of severe clinical events in a nationwide cohort study in China. A recent meta-analysis that evaluated the effects of cancer on patients with COVID-19 also showed that people with cancer were more susceptible to COVID-19 especially for those who had lung cancer than those without lung cancer (Yang, Chai et al., 2021). A meta-analysis

that was performed to evaluate the association of chronic kidney disease demonstrated that COVID-19 patients with pre-existing chronic kidney disease had significantly increased risks of progression to a severe condition and even death (Wang, Luo et al., 2021). Another study that examined the clinical courses of critically ill COVID-19 patients with and without pre-existing chronic kidney disease suggested that underlying kidney disease confers higher risk for individuals with COVID-19 with poorer COVID-19 outcomes (Flythe et al., 2021). Therefore, clinicians should closely monitor CKD patients with suspected COVID-19 to prevent disease progression. People with specific comorbid and underlying conditions are at high risk for COVID-19 severity and mortality. Hence, these population groups should be prioritized for access to COVID-19 vaccination regardless of their geographical location.

There are several limitations to this systematic review and metaanalysis. First, most of the studies included in the meta-analysis were retrospective and conducted in different countries, settings and variation in reporting of medical conditions may be present. Second, high heterogeneity among included studies might be due to the large variation among studies in the sample size. Third, there was heterogeneity in the definition of moderate and severe cases of COVID-19 patients, which might have contributed to the high heterogeneity of the meta-analysis. Fourth, as our topic was related to current pandemic and we already initiated literature searches hence we failed to register in the PROSPERO. However, during systematic processes involved in our literature review we strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. Despite these limitations, to the best of our knowledge, our study is the first systematic review and meta-analysis that examined comorbidities among severe and non-severe COVID-19 patients by including a large number of high-quality studies from Asian and non-Asian countries with large sample sizes.

5 | CONCLUSION

In conclusion, this systemic review and meta-analysis showed that the incidence of hypertension, diabetes, cardiovascular disease and chronic kidney disease was significantly higher in severe compared to non-severe patients in both Asian and non-Asian population. Despite the continuous efforts to prevent and reduce severity of the disease the COVID-19 pandemic is exacting enormous medical and economic tolls on human life. Timely identification of comorbidities predictive for severe disease and ICU admission, can help frontline health workers such as doctors and nurses to effectively prioritize individual at risk in countries with limited resources. Patients with comorbidities have a tendency to develop severe or critical disease and have a poor disease outcome. More attention should be given to the care of patients with pre-existing comorbidities. More well designed and high-quality randomized-control studies that use standardized patient selection are needed to confirm our findings.

ACKNOWLEDGEMENTS

Not applicable.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

AP, LH, MG and QHZ: conceptualization. AP, LH, MG and CFW: methodology. AP, LH, MG: statistical analysis. AP, LH, MG: data extraction and management. AP, LH, MG and QHZ: writing—original draft preparation. AP, LH, MG, QHZ and CFW: writing—review and editing. QHZ: supervision. All authors contributed to the article and approved the submitted version.

ETHICAL APPROVAL

Ethical review and approval is not required as this is systemic review and meta-analysis.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are available from the studies included in this meta-analysis.

ORCID

Mohan Giri (D) https://orcid.org/0000-0001-8588-5482

REFERENCES

- Abohamr, S. I., Abazid, R. M., Aldossari, M. A., Amer, H. A., Badhawi, O. S., Aljunaidi, O. M., Alzarzour, S. H., Saadeddin, H. M., Bhat, F. A., & Elsheikh, E. (2020). Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia. *Saudi Medical Journal*, 41(11), 1217–1226. https://doi.org/10.15537/ smj.2020.11.25495
- Alqahtani, A. M., AlMalki, Z. S., Alalweet, R. M., Almazrou, S. H., Alanazi, A. S., Alanazi, M. A., AlShehri, A. A., & AlGhamdi, S. (2020). Assessing the severity of illness in patients with Coronavirus Disease in Saudi Arabia: A retrospective descriptive cross-Sectional Study. *Frontiers in Public Health*, *8*, 593256. https://doi.org/10.3389/fpubh.2020.593256
- Al-Salameh, A., Lanoix, J.-P., Bennis, Y., Andrejak, C., Brochot, E., Deschasse, G., Dupont, H., Goeb, V., Jaureguy, M., Lion, S., Maizel, J., Moyet, J., Vaysse, B., Desailloud, R., Ganry, O., Schmit, J.-L., & Lalau, J.-D. (2021). Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. *Diabetes/ Metabolism Research and Reviews*, 37(3), e3388. https://doi. org/10.1002/dmrr.3388
- Argenziano, M. G., Bruce, S. L., Slater, C. L., Tiao, J. R., Baldwin, M. R., Barr, R. G., Chang, B. P., Chau, K. H., Choi, J. J., Gavin, N., Goyal, P., Mills, A. M., Patel, A. A., Romney, M.-L., Safford, M. M., Schluger, N. W., Sengupta, S., Sobieszczyk, M. E., Zucker, J. E., ... Chen, R. (2020). Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. *BMJ*, 369, m1996. https://doi.org/10.1136/bmj.m1996
- Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazancioglu, S., Kosovali,
 B. D., Ozbay, B. O., Gok, G., Turan, I. O., Yilmaz, G., Gonen, C. C., &
 Yilmaz, F. M. (2020). Clinical and laboratory features of COVID-19:
 Predictors of severe prognosis. *International Immunopharmacology*, 88, 106950. https://doi.org/10.1016/j.intimp.2020.106950
- Buckner, F. S., McCulloch, D. J., Atluri, V., Blain, M., McGuffin, S. A., Nalla, A. K., Huang, M.-L., Greninger, A. L., Jerome, K. R., Cohen, S. A.,

Neme, S., Green, M. L., Chu, H. Y., & Kim, H. N. (2020). Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. *Clinical Infectious Diseases*, 71(16), 2167–2173. https://doi.org/10.1093/cid/ciaa632

- Cao, J., Zheng, Y., Luo, Z., Mei, Z., Yao, Y., Liu, Z., Liang, C., Yang, H., Song, Y., Yu, K., Gao, Y., Zhu, C., Huang, Z., Qian, J., & Ge, J. (2020). Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. *Theranostics*, 10(21), 9663– 9673. https://doi.org/10.7150/thno.47980
- Cao, Z., Li, T., Liang, L., Wang, H., Wei, F., Meng, S., Cai, M., Zhang, Y., Xu, H., Zhang, J., & Jin, R. (2020). Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. *PLoS One*, *15*(6), e0234764. https://doi.org/10.1371/journal.pone.0234764
- Cattelan, A. M., Di Meco, E., Trevenzoli, M., Frater, A., Ferrari, A., Villano, M., Gomiero, F., Carretta, G., & Sasset, L. (2020). Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: A comparative study. BMC Infectious Diseases, 20(1), 934. https://doi.org/10.1186/s1287 9-020-05647-7
- Del Sole, F., Farcomeni, A., Loffredo, L., Carnevale, R., Menichelli, D., Vicario, T., Pignatelli, P., & Pastori, D. (2020). Features of severe COVID-19: A systematic review and meta-analysis. *European Journal* of Clinical Investigation, 50(10), e13378. https://doi.org/10.1111/ eci.13378
- Du, R.-H., Liu, L.-M., Yin, W., Wang, W., Guan, L.-L., Yuan, M.-L., Li, Y.-L., Hu, Y., Li, X.-Y., Sun, B., Peng, P., & Shi, H.-Z. (2020). Hospitalization and critical care of 109 decedents with COVID-19 Pneumonia in Wuhan, China. Annals of the American Thoracic Society, 17(7), 839– 846. https://doi.org/10.1513/AnnalsATS.202003-225OC
- Ferguson, J., Rosser, J. I., Quintero, O., Scott, J., Subramanian, A., Gumma, M., Rogers, A., & Kappagoda, S. (2020). Characteristics and outcomes of Coronavirus Disease patients under nonsurge conditions, Northern California, USA, March-April 2020. Emerging Infectious Diseases, 26(8), 1679–1685. https://doi.org/10.3201/ eid2608.201776
- Filardo, T. D., Khan, M. R., Krawczyk, N., Galitzer, H., Karmen-Tuohy, S., Coffee, M., Schaye, V. E., Eckhardt, B. J., & Cohen, G. M. (2020). Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). *PLoS One*, 15(11), e0242760. https://doi.org/10.1371/journ al.pone.0242760
- Flythe, J. E., Assimon, M. M., Tugman, M. J., Chang, E. H., Gupta, S., Shah, J., Sosa, M. A., Renaghan, A. D., Melamed, M. L., Wilson, F. P., Neyra, J. A., Rashidi, A., Boyle, S. M., Anand, S., Christov, M., Thomas, L. F., Edmonston, D., & Leaf, D. E. (2021). Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to tntensive care units in the United States. *American Journal of Kidney Diseases*, 77(2), 190–203.e1. https://doi. org/10.1053/j.ajkd.2020.09.003
- Garibaldi, B. T., Fiksel, J., Muschelli, J., Robinson, M. L., Rouhizadeh, M., Perin, J., Schumock, G., Nagy, P., Gray, J. H., Malapati, H., Ghobadi-Krueger, M., Niessen, T. M., Kim, B. S., Hill, P. M., Ahmed, M. S., Dobkin, E. D., Blanding, R., Abele, J., Woods, B., ... Gupta, A. (2021). Patient trajectories among persons hospitalized for COVID-19: A Cohort Study. *Annals of Internal Medicine*, 174(1), 33–41. https://doi. org/10.7326/M20-3905
- Giri, M., Puri, A., Wang, T., & Guo, S. (2020). Clinical features, comorbidities, complications and treatment options in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. Nursing Open, 8(3), 1077–1088. https://doi.org/10.1002/nop2.718
- Giustino, G., Croft, L. B., Stefanini, G. G., Bragato, R., Silbiger, J. J., Vicenzi, M., Danilov, T., Kukar, N., Shaban, N., Kini, A., Camaj, A., Bienstock, S. W., Rashed, E. R., Rahman, K., Oates, C. P., Buckley,

NursingOpen

S., Elbaum, L. S., Arkonac, D., Fiter, R., ... Goldman, M. E. (2020). Characterization of myocardial injury in patients with COVID-19. *Journal of the American College of Cardiology*, 76(18), 2043–2055. https://doi.org/10.1016/j.jacc.2020.08.069

- Gregoriano, C., Koch, D., Haubitz, S., Conen, A., Fux, C. A., Mueller, B., Bernasconi, L., Hammerer-Lercher, A., Oberle, M., Burgermeister, S., Reiter, H., Kutz, A., & Schuetz, P. (2020). Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: An observational analysis. Swiss Medical Weekly, 150, w20316. https://doi.org/10.4414/ smw.2020.20316
- Guan, W.-J., Ni, Z.-Y., Hu, Y. U., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., Du, B., Li, L.-J., Zeng, G., Yuen, K.-Y., Chen, R.-C., Tang, C.-L., Wang, T., Chen, P.-Y., Xiang, J., ... Zhong, N.-S. (2020). Clinical characteristics of Coronavirus Disease 2019 in China. *The New England Journal of Medicine*, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032
- Güner, R., Hasanoğlu, İ., Kayaaslan, B., Aypak, A., Kaya Kalem, A., Eser, F., Özdemir, B., Sarıcaoğlu, E. M., Ayhan, M., Aybar Bilir, Y., Özkoçak Turan, I., Erdem, D., Mutlu, N. M., Buzğan, T., Dinç, B., & Akıncı, E. (2020). COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey. *Turkish Journal of Medical Sciences*, *50*(8), 1801–1809. https://doi. org/10.3906/sag-2006-164
- Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020). Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 5(7), 1–8. https://doi.org/10.1001/jamac ardio.2020.1017
- Hong, K. S., Lee, K. H., Chung, J. H., Shin, K. C., Choi, E. Y., Jin, H. J., Jang, J. G., Lee, W., & Ahn, J. H. (2020). Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: A Brief Descriptive Study. *Yonsei Medical Journal*, 61(5), 431–437. https://doi.org/10.3349/ymj.2020.61.5.431
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. I., Zhang, L. I., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* (*London, England*), 395(10223), 497–506. https://doi.org/10.1016/ S0140-6736(20)30183-5
- Huang, D., Lian, X., Song, F., Ma, H., Lian, Z., Liang, Y., Qin, T., Chen, W., & Wang, S. (2020). Clinical features of severe patients infected with 2019 novel coronavirus: A systematic review and metaanalysis. *Annals of Translational Medicine*, 8(9), 576. https://doi. org/10.21037/atm-20-2124
- Huang, R., Zhu, L. I., Xue, L., Liu, L., Yan, X., Wang, J., Zhang, B., Xu, T., Ji, F., Zhao, Y., Cheng, J., Wang, Y., Shao, H., Hong, S., Cao, Q. I., Li, C., Zhao, X.-A., Zou, L., Sang, D., ... Wu, C. (2020). Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. *PLoS Neglected Tropical Diseases*, 14(5), e0008280. https://doi.org/10.1371/journ al.pntd.0008280
- Israelsen, S. B., Kristiansen, K. T., Hindsberger, B., Ulrik, C. S., Andersen, O., Jensen, M., Andersen, S., Rasmussen, C., Jørgensen, H. L., Østergaard, C., Lindhardt, B. Ø., Kronborg, G., & Benfield, T. (2020). Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020. Danish Medical Journal, 67(6), A05200313.
- Jourdes, A., Lafaurie, M., Martin-Blondel, G., Delobel, P., Faruch, M., Charpentier, S., Minville, V., Silva, S., Thalamas, C., Sommet, A., & Moulis, G. (2020). Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort. *La Revue De Médecine Interne*, 41(11), 732–740. https://doi.org/10.1016/j. revmed.2020.08.006

- Kaeuffer, C., Le Hyaric, C., Fabacher, T., Mootien, J., Dervieux, B., Ruch, Y., Hugerot, A., Zhu, Y.-J., Pointurier, V., Clere-Jehl, R., Greigert, V., Kassegne, L., Lefebvre, N., Gallais, F., Meyer, N., Hansmann, Y., Hinschberger, O., & Danion, F. (2020). Clinical characteristics and risk factors associated with severe COVID-19: Prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. Eurosurveillance, 25(48), 2000895. https://doi. org/10.2807/1560-7917.ES.2020.25.48.2000895
- Khamis, F., Al-Zakwani, I., Al Naamani, H., Al Lawati, S., Pandak, N., Omar, M. B., Al Bahrani, M., Bulushi, Z. A., Al Khalili, H., Al Salmi, I., Al Ismaili, R., & Al Awaidy, S. T. (2020). Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. *Journal of Infection and Public Health*, 13(7), 906–913. https://doi.org/10.1016/j.jiph.2020.06.002
- Khan, A., Althunayyan, S., Alsofayan, Y., Alotaibi, R., Mubarak, A., Arafat, M., Assiri, A., & Jokhdar, H. (2020). Risk factors associated with worse outcomes in COVID-19: A retrospective study in Saudi Arabia. *Eastern Mediterranean Health Journal*, 26(11), 1371–1380. https://doi.org/10.26719/emhj.20.130
- Lee, J. Y., Hong, S. W., Hyun, M., Park, J. S., Lee, J. H., Suh, Y. S., Kim, D. H., Han, S.-W., Cho, C.-H., & Kim, H. A. (2020). Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. International Journal of Infectious Diseases, 98, 462– 466. https://doi.org/10.1016/j.ijid.2020.07.017
- Lee, S.-G., Park, G. U., Moon, Y. R., & Sung, K. (2020). Clinical characteristics and risk factors for fatality and severity in patients with Coronavirus Disease in Korea: A nationwide population-based retrospective study using the Korean health insurance review and assessment service (HIRA) database. *International Journal of Environmental Research and Public Health*, 17(22), 8559. https://doi. org/10.3390/ijerph17228559
- Li, C., Jiang, J., Wang, F., Zhou, N., Veronese, G., Moslehi, J. J., Ammirati, E., & Wang, D. W. (2020). Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. *Journal of Molecular and Cellular Cardiology*, 147, 74–87. https://doi.org/10.1016/j.yjmcc.2020.08.008
- Li, K., Wu, J., Wu, F., Guo, D., Chen, L., Fang, Z., & Li, C. (2020). The clinical and chest CT features associated with severe and critical COVID-19 Pneumonia. *Investigative Radiology*, 55(6), 327–331. https://doi.org/10.1097/RLI.00000000000672
- Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z., Renz, H., Liu, X., Xie, J., Xie, M., & Zhao, J. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *The Journal of Allergy and Clinical Immunology*, 146(1), 110–118. https://doi.org/10.1016/j. jaci.2020.04.006
- Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., Li, S., & He, J. (2020). Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. *The Lancet Oncology*, *21*(3), 335–337. https://doi.org/10.1016/S1470-2045(20)30096-6
- Lombardi, C. M., Carubelli, V., Iorio, A., Inciardi, R. M., Bellasi, A., Canale, C., Camporotondo, R., Catagnano, F., Dalla Vecchia, L. A., Giovinazzo, S., Maccagni, G., Mapelli, M., Margonato, D., Monzo, L., Nuzzi, V., Oriecuia, C., Peveri, G., Pozzi, A., Provenzale, G., ... Senni, M. (2020). Association of troponin levels with mortality in italian patients hospitalized with Coronavirus Disease 2019: Results of a multicenter study. JAMA Cardiology, 5(11), 1274–1280. https://doi. org/10.1001/jamacardio.2020.3538
- Lv, Z., Cheng, S., Le, J., Huang, J., Feng, L., Zhang, B., & Li, Y. (2020). Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: A retrospective cohort study. *Microbes and Infection*, 22(4–5), 195–199. https://doi. org/10.1016/j.micinf.2020.05.007
- Matangila, J. R., Nyembu, R. K., Telo, G. M., Ngoy, C. D., Sakobo, T. M., Massolo, J. M., Muyembe, B. M., Mvwala, R. K., Ilunga, C. K.,

Limbole, E. B., Ntalaja, J. M., & Kongo, R. M. (2020). Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study. *PLoS One*, *15*(12), e0244272. https:// doi.org/10.1371/journal.pone.0244272

- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Medicine*, 6(7), e1000097. https://doi. org/10.1371/journal.pmed.1000097
- Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., Xu, Y., Cao, Z., & Gao, Z. (2020). Role of angiotensinconverting enzyme 2 (ACE2) in COVID-19. *Critical Care (London, England)*, 24(1), 422. https://doi.org/10.1186/s13054-020-03120-0
- Omrani, A. S., Almaslamani, M. A., Daghfal, J., Alattar, R. A., Elgara, M., Shaar, S. H., Ibrahim, T. B. H., Zaqout, A., Bakdach, D., Akkari, A. M., Baiou, A., Alhariri, B., Elajez, R., Husain, A. A. M., Badawi, M. N., Abid, F. B., Abu Jarir, S. H., Abdalla, S., Kaleeckal, A., ... Al-Kuwari, H. M. (2020). The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. BMC Infectious Diseases, 20(1), 777. https://doi.org/10.1186/s12879-020-05511-8
- Ortiz-Brizuela, E., Villanueva-Reza, M., González-Lara, M. F., Tamez-Torres, K. M., Román-Montes, C. M., Díaz-Mejía, B. A., Pérez-García, E., Olivas-Martínez, A., Rajme-López, S., Martinez-Guerra, B. A., de-León-Cividanes, N. A., Fernández-García, O. A., Guerrero-Torres, L., Torres-González, L., & Carrera-Patiño, F. A. (2020). Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in mexico city: A prospective cohort study. *Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion*, 72(3), 165–177. https://doi.org/10.24875/RIC.20000211
- Oud, L., & Garza, J. (2021). Epidemiology and outcomes of invasive mechanical ventilation without ICU admission in acute care hospitals in Texas: A population-based cohort study. *Journal of Critical Care*, 61, 107–114. https://doi.org/10.1016/j.jcrc.2020.10.019
- Pellaud, C., Grandmaison, G., Hoa Phong, P. H. T., Baumberger, M., Carrel, G., Ksouri, H., Erard, V., Chuard, C., Hayoz, D., & Sridharan, G. (2020). Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area - A retrospective cohort study. Swiss Medical Weekly, 150, w20314. https://doi.org/10.4414/smw.2020.20314
- Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with Coronavirus disease 2019 in New York City: Prospective cohort study. *BMJ*, 369, m1966. https://doi. org/10.1136/bmj.m1966
- Popov, G. T., Baymakova, M., Vaseva, V., Kundurzhiev, T., & Mutafchiyski, V. (2020). Clinical characteristics of hospitalized patients with COVID-19 in Sofia, Bulgaria. Vector-Borne and Zoonotic Diseases, 20(12), 910–915. https://doi.org/10.1089/vbz.2020.2679
- Raad, M., Dabbagh, M., Gorgis, S., Yan, J., Chehab, O., Dagher, C., Jamoor, K., Hussein, I. H., Cook, B., Van Harn, M., Singh, G., McCord, J., & Parikh, S. (2020). Cardiac injury patterns and inpatient outcomes among patients admitted with COVID-19. *The American Journal* of *Cardiology*, 133, 154–161. https://doi.org/10.1016/j.amjca rd.2020.07.040
- Reilev, M., Kristensen, K. B., Pottegård, A., Lund, L. C., Hallas, J., Ernst, M. T., Christiansen, C. F., Sørensen, H. T., Johansen, N. B., Brun, N. C., Voldstedlund, M., Støvring, H., Thomsen, M. K., Christensen, S., Gubbels, S., Krause, T. G., Mølbak, K., & Thomsen, R. W. (2020). Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: A nationwide cohort. *International Journal of Epidemiology*, 49(5), 1468–1481. https://doi.org/10.1093/ije/dyaa140
- Samuels, S., Niu, J., Sareli, C., & Eckardt, P. (2021). The epidemiology and predictors of outcomes among confirmed COVID-19 cases in

a large community healthcare system in South Florida. *Journal of Community Health*, 46(4), 822–831. https://doi.org/10.1007/s1090 0-020-00957-y

- Schönfeld, D., Arias, S., Bossio, J. C., Fernández, H., Gozal, D., & Pérez-Chada, D. (2021). Clinical presentation and outcomes of the first patients with COVID-19 in Argentina: Results of 207079 cases from a national database. *PLoS One*, 16(2), e0246793. https://doi. org/10.1371/journal.pone.0246793
- Shabrawishi, M., Al-Gethamy, M. M., Naser, A. Y., Ghazawi, M. A., Alsharif, G. F., Obaid, E. F., Melebari, H. A., Alamri, D. M., Brinji, A. S., Al Jehani, F. H., Almaimani, W., Ekram, R. A., Alkhatib, K. H., & Alwafi, H. (2020). Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One*, *15*(8), e0237130. https://doi.org/10.1371/journal.pone.0237130
- Shahriarirad, R., Khodamoradi, Z., Erfani, A., Hosseinpour, H., Ranjbar, K., Emami, Y., Mirahmadizadeh, A., Lotfi, M., Shirazi Yeganeh, B., Dorrani Nejad, A., Hemmati, A., Ebrahimi, M., & Moghadami, M. (2020). Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infectious Diseases, 20(1), 427. https://doi.org/10.1186/s12879-020-05128-x
- Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., Huang, H., Yang, B., & Huang, C. (2020). Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. *China. JAMA Cardiology*, *5*(7), 802–810. https://doi. org/10.1001/jamacardio.2020.0950
- Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003). Methodological index for non-randomized studies (minors): Developmentandvalidationofanewinstrument. ANZ Journal of Surgery, 73(9), 712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x
- Stefan, G., Mehedinti, A. M., Andreiana, I., Zugravu, A. D., Cinca, S., Busuioc, R., Miler, I., Stancu, S., Petrescu, L., Dimitriu, I., Moldovanu, E., Crasnaru, D. E., Gugonea, G., Georgescu, V., Strambu, V. D., & Capusa, C. (2021). Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. *Renal Failure*, 43(1), 49–57. https://doi. org/10.1080/0886022X.2020.1853571
- Sulejmani, A., Galimberti, E., Giacobone, C., Milano, A., Scopetta, E., Intra, J., Falbo, R., Sarto, C., Leoni, V., & Brambilla, P. (2021). Baseline characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: A retrospective study. *Scandinavian Journal of Clinical and Laboratory Investigation*, 81(1), 18–23. https:// doi.org/10.1080/00365513.2020.1846211
- Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., Demertzis, Z., Hanna, Z., Failla, A., Dagher, C., Chaudhry, Z., Vahia, A., Abreu Lanfranco, O., Ramesh, M., Zervos, M. J., Alangaden, G., Miller, J., & Brar, I. (2020). Clinical characteristics and morbidity associated with Coronavirus Disease 2019 in a series of patients in metropolitan Detroit. JAMA Network Open, 3(6), e2012270. https:// doi.org/10.1001/jamanetworkopen.2020.12270
- Tabata, S., Imai, K., Kawano, S., Ikeda, M., Kodama, T., Miyoshi, K., Obinata, H., Mimura, S., Kodera, T., Kitagaki, M., Sato, M., Suzuki, S., Ito, T., Uwabe, Y., & Tamura, K. (2020). Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: A retrospective analysis. *The Lancet Infectious Diseases*, 20(9), 1043–1050. https://doi.org/10.1016/S1473-3099(20)30482-5
- Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., Chen, H., Wang, D., Liu, N., Liu, D., Chen, G., Zhang, Y., Li, D., Li, J., Lian, H., Niu, S., Zhang, L., & Zhang, J. (2020). Characteristics of COVID-19 infection in Beijing. *The Journal of Infection*, 80(4), 401–406. https://doi. org/10.1016/j.jinf.2020.02.018
- Tignanelli, C. J., Ingraham, N. E., Sparks, M. A., Reilkoff, R., Bezdicek, T., Benson, B., Schacker, T., Chipman, J. G., & Puskarich, M. A. (2020). Antihypertensive drugs and risk of COVID-19? *The Lancet Respiratory Medicine*, 8(5), e30–e31. https://doi.org/10.1016/ S2213-2600(20)30153-3

<u>NursingOpen</u>

Turcotte, J. J., Meisenberg, B. R., MacDonald, J. H., Menon, N., Fowler, M. B., West, M., Rhule, J., Qureshi, S. S., & MacDonald, E. B. (2020). Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital. *PLoS One*, 15(8), e0237558. https://doi. org/10.1371/journal.pone.0237558

Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., Huang, X., Lv, J., Luo, Y., Shen, L., Yang, H., Huang, G., & Yang, R. (2020). Clinical features and treatment of COVID-19 patients in northeast Chongqing. *Journal of Medical Virology*, 92(7), 797–806. https://doi.org/10.1002/jmv.25783

- Wang, B., Luo, Q., Zhang, W., Yu, S., Cheng, X., Wang, L., Chen, X., & Chen, Y. (2021). The involvement of chronic kidney disease and acute kidney injury in disease severity and mortality in patients with COVID-19: A meta-analysis. *Kidney & Blood Pressure Research*, 46(1), 17-30. https://doi.org/10.1159/000512211
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
- Wang, W., Xin, C., Xiong, Z., Yan, X., Cai, Y., Zhou, K., Xie, C., Zhang, T., Wu, X., Liu, K., Li, Z., & Chen, J. (2020). Clinical characteristics and outcomes of 421 patients with Coronavirus Disease 2019 treated in a Mobile cabin hospital. *Chest*, 158(3), 939–946. https://doi. org/10.1016/j.chest.2020.05.515
- Wang, Y., Zheng, Y., Tong, Q., Wang, L., Lv, G., Xi, Z., & Liu, W. (2020). Cardiac injury and clinical course of patients with Coronavirus Disease 2019. Frontiers in Cardiovascular Medicine, 7, 147. https:// doi.org/10.3389/fcvm.2020.00147
- Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020). Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. *Clinical Infectious Diseases*, 71(15), 769–777. https://doi.org/10.1093/cid/ciaa272
- Wei, Y., Zeng, W., Huang, X., Li, J., Qiu, X., Li, H., Liu, D., He, Z., Yao, W., Huang, P., Li, C., Zhu, M., Zhong, C., Zhu, X., & Liu, J. (2020). Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: A single-center descriptive study. BMC Infectious Diseases, 20(1), 549. https://doi. org/10.1186/s12879-020-05252-8
- World Health Organization. (2021). COVID-19 Weekly Epidemiological Update. https://www.who.int/publications/m/item/weekly-epide miological-update-on-covid-19--27-april-2021 (accessed 29 April 2021)
- Wu, J., Li, W., Shi, X., Chen, Z., Jiang, B., Liu, J., Wang, D., Liu, C., Meng, Y., Cui, L., Yu, J., Cao, H., & Li, L. (2020). Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). *Journal* of Internal Medicine, 288(1), 128–138. https://doi.org/10.1111/ joim.13063
- Xiong, F., Tang, H., Liu, L., Tu, C., Tian, J.-B., Lei, C.-T., Liu, J., Dong, J.-W., Chen, W.-L., Wang, X.-H., Luo, D., Shi, M., Miao, X.-P., & Zhang, C. (2020). Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. *Journal of the American Society of Nephrology*, *31*(7), 1387–1397. https://doi.org/10.1681/ASN.2020030354
- Xiong, S., Liu, L., Lin, F., Shi, J., Han, L., Liu, H., He, L., Jiang, Q., Wang, Z., Fu, W., Li, Z., Lu, Q., Chen, Z., & Ding, S. (2020). Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: A single-centered, retrospective, observational study. BMC Infectious Diseases, 20(1), 787. https://doi.org/10.1186/s12879-020-05452-2
- Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. *International Journal of Infectious Diseases*, 94, 91–95. https://doi.org/10.1016/j.ijid.2020.03.017

- Yang, L., Chai, P., Yu, J., & Fan, X. (2021). Effects of cancer on patients with COVID-19: A systematic review and meta-analysis of 63,019 participants. *Cancer Biology & Medicine*, 18(1), 298–307. https://doi. org/10.20892/j.issn.2095-3941.2020.0559
- Yang, L., Liu, J., Zhang, R., Li, M., Li, Z., Zhou, X., Hu, C., Tian, F., Zhou, F., & Lei, Y. (2020). Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study. *Journal of Clinical Virology*, 129, 104475. https://doi.org/10.1016/j.jcv.2020.104475
- Yazdanpanah, Y., Diallo, A., Paul, C., Mercier, N., Le mestre, S., Petrovsanchez, V., Andrejak, C., Chirouze, C., Malvy, D., Deplanque, D., Dubos, F., Rossignol, P., Etienne, M., Rossignol, B., Levy-marchal, C., Gilg, M., Gigante, T., Marine, B., Hulot, J.-S., ... El sanharawi, M. (2021). Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. *Journal of Medical Virology*, *93*(4), 2149–2159. https://doi.org/10.1002/jmv.26601
- Yin, T., Li, Y., Ying, Y., & Luo, Z. (2021). Prevalence of comorbidity in Chinese patients with COVID-19: Systematic review and metaanalysis of risk factors. BMC Infectious Diseases, 21(1), 200. https:// doi.org/10.1186/s12879-021-05915-0
- Zhang, G., Hu, C., Luo, L., Fang, F., Chen, Y., Li, J., Peng, Z., & Pan, H. (2020). Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *Journal of Clinical Virology*, 127, 104364. https://doi.org/10.1016/j.jcv.2020.104364
- Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*, 75(7), 1730– 1741. https://doi.org/10.1111/all.14238
- Zhang, J. J. Y., Lee, K. S., Ang, L. W., Leo, Y. S., & Young, B. E. (2020). Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. *Clinical Infectious Diseases*, 71(16), 2199– 2206. https://doi.org/10.1093/cid/ciaa576
- Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020). COVID-19 and the cardiovascular system. *Nature Reviews Cardiology*, 17(5), 259–260. https://doi.org/10.1038/s41569-020-0360-5
- Zhou, J., Sun, J., Cao, Z., Wang, W., Huang, K., Zheng, F., Xie, Y., Jiang, D., & Zhou, Z. (2020). Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China. *Medicine*, 99(34), e21824. https://doi.org/10.1097/MD.00000000021824
- Zhou, Y., Chi, J., Lv, W., & Wang, Y. (2021). Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes/Metabolism Research and Reviews, 37(2), e3377. https:// doi.org/10.1002/dmrr.3377
- Zhou, Y., Yang, Q., Chi, J., Dong, B., Lv, W., Shen, L., & Wang, Y. (2020). Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and metaanalysis. *International Journal of Infectious Diseases*, 99, 47–56. https://doi.org/10.1016/j.ijid.2020.07.029

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Puri, A., He, L., Giri, M., Wu, C., & Zhao, Q. (2022). Comparison of comorbidities among severe and non-severe COVID-19 patients in Asian versus non-Asian populations: A systematic review and meta-analysis. *Nursing Open*, 9, 733-751. https://doi.org/10.1002/nop2.1126

WILEY